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ABSTRACT

Design and Synthesis of Cationic Steroid Antimicrobial Compounds, Synthesis of Glycolipids
Recognized by Natural Killer T cells and Development of TLR-2 and TLR-6 Heterodimer
Binders and Studies of Their Immunology Activities

Yanshu Feng
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Cationic steroid antimicrobial agents (CSAs) are a family of bile acid derivatives. These
compounds are amphiphilic and mimic endogenous antimicrobial peptides. The antimicrobial
activities of CSA-13 have been investigated and due to portent bactericidal activities and low
toxicity, a large amount of CSA-13 is demanded for clinic trails and other antimicrobial
applications. During our studies, we optimized the synthetic route of CSA-13, so that it can be
prepared at the kilogram, even in tons scale. We investigated three routes and one of them is
suitable for industry, because only recrystallization is needed in the synthesis.
Natural killer T cells (NKT cells) are a kind of lymphocyte that bridge the adaptive
immune system with the innate immune system. Once stimulated by glycolipids, NKT cells
influence immune responses. To search for better glycolipid ligands, scientists have isolated
many natural products to get inspiration. Thrautochysides A-C was isolated from a group of
marine protists. These compounds have an interesting structure on their sphingosine lipid chains.
We finished the total synthesis of thraustochyside B, and made substantial progress toward the
synthesis of thraustochyside A.
Toll like receptors (TLRs) are integral components of the innate immune system. They
recognize antigens and induce dendritic cells to give immune responses. TLR1, TLR2 and TLR6
recognize lipopetides, and these TLRs function as heterodimers. TLR1/TLR2 dimer recognition
gives inflammatory responses, and TLR2/TLR6 dimer recognition gives immunomodulatory
responses. We used modeling of TLRs to find a compound, which can fill the lipid binding
pockets of the TLR2 and TLR6 dimer. In our study, we found the peptide chain of the antigen
Pam2CSK4 can be replaced by a water soluble polyamine, which confirmed the function of the
peptide to increase the water solubility.
Keywords: Synthesis, Cationic steroid antimicrobial, glycolipids,TLR-1, TLR-6,
Immunology
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Chapter 1. Design and Synthesis of Cationic Steroid Antimicrobial Compounds

1.1 Introduction
1.1.1 Diseases caused by bacteria
With the first observation of bacteria by Antonie van Leeuwenhoek in 1676,1 people
started to find that many diseases are caused by bacteria.

Diphtheria, granulomatous

lymphadenitis, pneumonitis, pharyngitis, skin infections, and endocarditis are caused by strains
of Corynebacterium.2 As a result, the war against the diseases caused by various types of
bacteria became significant.
Pseudomonas aeruginosa is found almost everywhere throughout the world, in places
such as soil, water, and skin. It uses a wide range of organic material for food, even diesel. It
infects the pulmonary tract, urinary tract, burns, wounds, and causes diffuse bronchopneumonia,
urinary tract catheterization, hemorrhage and necrosis.3
Staphylococcus aureus was found in 1880.4 Many diseases are caused by S. aureus, such
as pneumonia, meningitis, osteomyelitis, endocarditis, and sepsis. At this point, it is one of the
five most common causes of nosocomial infections.5

1.1.2 Bacteria differentiation by membrane structure

1

Bacteria are divided into two domains by their cell wall structure and compositions:
Gram-positive bacteria and Gram-negative bacteria.6 To characterize a bacteria sample, the
Gram-staining method technique is used first.7 A certain dye, called crystal violet is used to treat
the bacteria. Then, iodine is added to react with crystal violet to generate a larger crystal. For
Gram-positive bacteria, the dye will enter the bacteria cell through the membrane, and the
formed larger crystal is not allowed to traverse in the bacteria cell membrane, which keeps the
dye in the cell. That will cause the bacteria to become purple.8 For Gram-negative bacteria, the
outer membrane prevents the dye entering the bacteria cell, thus, after staining, they remain
colorless or pink.

1.1.3 Drug resistance of bacteria
Since the discovery of penicillin, many antimicrobial drugs have been developed, and
people benefited from them.9 However, the extensive use of antibiotics, within medicine and
veterinary medicine, has resulted in increased resistance in bacterial isolates due to the ability of
bacteria to evolve and adapt to selective pressures.10 The longer the duration of exposure to an
antibiotic, the greater the risk of the development of resistance. As resistance becomes more
common, there becomes a greater need for alternative treatments. P. aeruginosa is naturally
resistant to a large range of antibiotics and may demonstrate additional resistance after
unsuccessful treatment.11 One of the super bacteria, methicillin resistant S. aureus (MRSA),
have become resistant to most antibiotics.12, 13, 14 Statistically, to bring a new drug to market, ten
years is needed; however, bacteria can usually engender antibiotic resistance in only two years.
2

Due to increased microbial resistance, cationic antimicrobial peptides (AMPs) isolated
from nature, such as magainins15 and cecropins,16 are attracting attention in the antibiotic
development community.17, 18, 19 They are important components of natural defenses in living
organisms. These compounds consist of amino acids with both polar (lycine and arginine) and
non-polar residue. In their active conformations, these compounds are typically amphiphilic,
with a hydrophobic face and a cationic polar face,20 and generally target the bacterial membrane,
disrupt the barrier, and kill the bacteria. These features produce greater affinity for prokaryotic
membrane surfaces (comprised of lipids such as lipid A, Figure 1-1), which are typically
negatively charged, unlike eukaryotic membranes.21

Figure 1-1: Structure of Lipid A
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The human body also produces antimicrobial peptides, including defensins,22
cathelicidins23 and histatins. As a key component of cathelicidins, LL-37 is found throughout the
body, such as in tears, gastrointestinal extract, semen, and et al.

1.1.4 Bactericidal mechanisms of AMPs
The microbial killing mechanism of AMPs is still not fully understood. There are several
permeabilization mechanisms have been proposed to explain the bactericidal activity.24 In the
“barrel-stave model”, the peptides aggregate and insert into the membrane. The hydrophobic
surfaces of the peptides face the membrane lipid chains, whereas the hydrophilic surfaces form
the lumen. Another bactericidal mechanism of antimicrobial peptides is the “carpet model”,
shown in Figure 1-2

Figure 1-2. Carpet model of bactericidal activity of antimicrobial peptides
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The cationic residues bind to the membrane surface via ionic interactions. Some of the
antimicrobial peptide molecules re-orient back to back to separate the hydrophobic residues with
the hydrophobic core of the membrane, and disrupt the membrane. The cytoxicity caused by the
aggregation of this kind of detergent like compound has also been reported in the studies of
amitriptyline.25
Unlike the “barrel-stave” model, the “torroidal-pore model” is more like the “carpet
model”. Peptides associate with the polar surface and induce the membrane to bend through the
membrane bilayer to form transmembrane pores. On the channel walls, the hydrophobic surface
face inside, which allow lager molecules to traverse through the cell membrane and cause
bacteria to die.

1.1.5 Selectivity of antimicrobial peptide between prokaryotic and eukaryotic cells
For clinical use, antimicrobial peptides, especially LL-37, have good selectivity between
prokaryotic and eukaryotic cells.26 Both prokaryotic and eukaryotic membrane surfaces are
polar.

In prokaryotic cytoplasmic membranes, anionic PG (phosphatidylglycerol) and CL

(cardiolipin) are the major components (Table 1-1), whereas the eukaryotic membrane is
composed principally of neutral PC (phosphatidylcholine) and sphingomyelin. There are four
cationic residues on LL-37, and it has a higher affinity to the bacteria membranes than human
cell membranes.

1.1.6 Development of CSAs
5

Generally, it is necessary for antibiotics to enter bacterial cells first to inhibit bacterial
duplication, such as quinolones and sulfonamides. To gain resistance, bacteria developed their
defense system by building biofilm to prevent drugs entering their cells,27 pumping out those
toxic compounds28 or releasing enzymes to degrade them.29 Unlike other antibiotic agents,
AMPs target bacteria cell membranes, which avoid those limitations.
However, there are still drawbacks that make the clinical use of antimicrobial peptides
challenging. AMPs are generally large in size, which makes them difficult and expensive in
producing on a large scale. Also, AMPs are relatively unstable due to proteolytic degradation in
the presence of proteases released by both human bodies and bacteria.30 Hence, use of smaller
molecules to mimic their behaviors may be more efficient. The design and synthesis of small
and stable molecules to mimic these peptides is being pursued in four groups.31, 32, 33, 34
During the studies of AMPs bactericidal activities, the enantiomer of LL-37 was found to
be equally effective,35 which leads our attention to the facially amphiphilic morphology. Cholic
acid is commercially available and inexpensive. By simple modification of the core structure,
facially amphiphilic molecules could be obtained.

Cationic steroid antimicrobial (CSA)

compounds are families of cholic acid-derived antimicrobial agents that mimic the activity of
natural antimicrobial peptides. We have prepared more than one hundred CSAs consisting of
different chain lengths on the side chains at position 3, 7 and 12, with free amino groups on the
terminals. Due to the stereochemistry of the oxygen atoms on the steroid scaffold, the amino
groups are predisposed to be on one face of the molecules, which induces the facial
amphiphilicity. Instead of oxygen, nitrogen was also tried in those side chain linkages. At
6

position 24, linkages of different chain lengths have also been made. E. Coli was used to test
their basic antimicrobial activities.

Of all the CSAs, CSA-13 (Figure 1-3) has been

characterized and studied in greatest depth due to its excellent activities (the range of minimum
bacteria inhibitory concentration (MIC) is from 35 µg/mL to 0.03 µg/mL against a broad range
of organisms).36

% Total membrane phospholipid
PE

PG

CL

PC

Proteus mirabilis

80

10

5

–

E. coli

80

15

–

–

Pseudomonas

60

21

11

–

B. anthracis

43

40

17

–

B. Subtilis

12

70

4

–

S. aureus

–

58

42

–

Mammalian liver

23

–

1

39

aeruginosa

plasma membrane

Table 1-1. Major phospholipid components15. PE, phosphatidylethanolamine
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CSA-8 is another well studied compound, because it helps to drop other antimicrobial
agents’ MICs dramatically. The value to estimate this property is called in the fractional
inhibitory concentration (FIC).

Figure 1-3: Structure of CSA-13 and CSA-8

1.2 Mechanism of CSA-13 as an antimicrobial agent
1.2.1 Membrane depolarization and antimicrobial activities of CSAs
1.2.1.1 Permeabilization of CSAs into E. coli outer membrane and inner membrane

8

E. coli strain ML-35p lacks lac permease, but is constitutive for plasmid-encoded
periplasmic β -lactamase, and expresses cytoplasmic β-galactosidase.

9

Figure 1-4: Permeabilization of CSAs into E. coli ML-35p outer membrane and inner membrane
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Nitrocefin was used to monitor the permeabilization of the outer membranes of E. coli
strain ML-35p. This molecule is not able to cross the outer membrane to access the periplasmic
space, unless there is permeabilization of the outer membrane. Once nitrocefin enters the
periplasm, the 4-membered lactam is cleaved by β-lactamase. The amino group generated
donates electrons to the conjugated π-system and causes color change that can be observed at
486 nm (Figure 1-4).
o-Nitrophenyl-3-D-galactoside (ONPG) was used to monitor the permeabilization of the
inner membranes of E. coli strain ML-35p. ONPG is not able to traverse the inner cytoplasmic
membrane without the help of permease. If it does traverse the cytoplasmic membrane, onitrophenol is produced by cytoplasmic β-galactosidase cleaving the glycosidic bond to cause
color change, monitored under 420 nm.
CSA-8, CSA-13 and CSA-54 were used in the permeabilization tests, and an
antimicrobial peptide, melittin, acted as control due to the strong effect of membrane
permeabilization. From Figure 1-4 we can see, the nitrocefin fluorescence increasing could be
detected right after any of all three CSAs were added, rather than melittin. This means the CSAs
caused permeation of the E. coli strain ML-35p outer membrane is more rapid than melittin. For
ONPG, adding CSA-13 and melittin helped the observation of the fluorescence increases. No
permeabilization was observed for CSA-8 and CSA-54 even at concentrations well above the
minimum bactericidal concentration (MBC). That argues that for CSA-8 and CSA-54, the
bactericidal activity does not involve cytoplasmic membrane disruptions.

11

1.2.1.2 Membrane depolarization
To test the depolarization of CSAs, 3, 3’-diethylthiadicarbocyanine iodide (DiS-C2 (5))
was used. This molecule is a type of lipophilic fluorescent stain for labeling membranes and
other hydrophobic structures.

It has a high extinction coefficient: polarity-dependent

fluorescence and short excited-state lifetime. Once applied to cells, this dye diffuses laterally
within the cellular membranes. The fluorescence of this environment-sensitive dye is greatly
enhanced in polarized membranes.

An excitation wavelength of 600 nm and an emission

wavelength of 660 nm were used to monitor depolarization (Table 1-2).
The dye was put into the cuvettes along with the bacteria cell suspension in buffer
(PH=7.0) at 37 °C. The baselines were determined after 7 mins. Measurements were taken
every 30s before and after the addition of CSAs in different concentrations.

12

Bacterial species

Lipid
compositi
on %
P P
E G

B.
polymyxa
B. cereus

Gra
mPositi
ve
bacte
ria

Gra
mNegat
ive
bacte
ria

6
0
4
3

E. facealis

0

S.
epidermis

0

S. aureus

0

MRSA

0

E. coli
K.
pneunoniae
P.
aeruginosa

8
5
8
2
6
0

CSA-13

CSA-54

CSA-8

Depolariza
tion at
MBC %

M
BC

Depolariza
tion at
MBC %

M
BC

Depolariza
tion at
MBC %

2.5

88.4

2.5

39.6

15

96.6

1

86.7

7

79.7

7

84.7

5.5

74

28
0

77.2

50

80.6

1

25

2.5

26.3

12

60.1

2.5

41.5

49

39.8

35

82.8

2

45.8

28

15.3

19

39

C M
L BC

3

8

4
0
2
7
9
0
5
7
5
7
1
5

1
7
1
9

5

1.5

10

5

6

2.5

12.
5

2
1

1
1

3.5

12

1
1
9
1
9

Table 1-2: Membrane depolarization ratios

Of the Gram-positive bacteria that were tested, E. faecalis was the most resistant to the
CSAs, which could be the result of the lack of PE and PG in the cell membranes. In the
membrane depolarization test, all the CSAs gave positive results by increasing the polarity of the
cell membrane, which was observed by the elevating fluorescent. 4*MBC was the highest
concentration of CSAs that were used as a control. The level of depolarization reached a
maximum from 1 min to 5 mins.

For Gram-positive bacteria, cyanine dye was used

straightforward because it entered the cytoplasmic membrane directly. Results showed that at
13

the concentration of the MBCs, membrane depolarization reached 50% to 90%. For Gramnegative bacteria, EDTA was used to allow the dye to traverse the outer membrane, and was
compared to CSA-8. In the experiment, the fluorescent dye accesses the cytoplasmic membrane
through the help of CSAs or EDTA to permeabilize the OM barrier. The phenomenon could be
observed by the loss of fluorescence after the addition of the agents under relatively low
concentration caused by incorporation of the dye in the cytoplasmic membrane. At the MBC and
above the CSAs, the fluorescence of the probe increased. This supported the idea that the
incorporation was competitive with the membrane depolarization.

By understanding the

relationship between the MBC and concentration depolarization required for, we were able to
correlate membrane depolarization with the bactericidal activity of the CSAs (Figure 1-5).

Figure 1-5: DiS-C2 (5) levels in the process of membrane depolarization

1.2.2 Resistance of Gram-negative and Gram-positive bacteria to CSA-13
1.2.2.1 Resistance of Gram-negative and Gram-positive bacteria to AMPs
14

Over 1,600 antimicrobial peptides (AMPs) have been isolated in nature, and bacteria have
been exposed to them for eons.38 As a result, it is not surprising that bacteria evolved means to
resist AMPs.

To avoid being killed by AMPs, some bacteria alter the structure of their

membrane components. For Gram-negative bacteria, modification of the lipid A containing
outer membrane by addition of cationic groups is the most common way to generate resistance. 39
However, this resistance does not come from the mutation of genes, thus, outside the presence of
AMPs, bacteria return to susceptible forms. Adding aminoarabinose on the lipid A has been
shown to be a means to obtain resistance. The modified lipid A has been detected in the
lipopolysaccharide (LPS) extraction. The procedures for analysis of this modification have been
well developed .40

1.2.2.2 Resistance of Gram-positive bacteria to CSA-13
Since CSAs mimic the actions of AMPs, we wanted to test the bacterial resistance to
CSAs and study the mechanism of action. Evaluation of the propensity of bacteria to generate
resistance to antibacterial agents can be performed using the following multiple challenge
procedures.

First, bacteria are exposed to incrementally varied concentrations of an

antimicrobial agent. The organisms that grow at the highest concentration of the antimicrobial
are cultured and re-exposed to the same reagents. The procedure is repeated, and the MIC and
MBC to the reagents are monitored. In multiple studies, 15 to 20 passages are performed and
bacterial resistance is observed with some antibacterial agents after only a few passages.

15

For Gram-positive bacteria, Staphylococcus aureus was used in the test (Figure 1-6).
After 10 serial passages, the MIC of ciprofloxacin increased to over 10 µg/ml. By 18 passages,
the MIC had increased to over 100 µg/ml. The MIC of vancomycin increased from 1 to 5-7
µg/ml over 20 passages, while variations in the MIC of CSA-13 were minor. Compared to
AMPs, similar results were obtained. Because the cytoplasma membrane is exposed to the
agents directly, there is not a large resistance to CSA-13 after 30 passages, as compared to other
antimicrobial agents. The highest MIC values measured were 1.2 µg/ml.

Figure 1-6: Serial Passage S. aureus

1.2.2.3 Resistance of Gram-negative bacteria to CSA-13
For Gram-negative bacteria, high resistance was observed against ciprofloxacin and
colistin. The MIC values against CSA-13 increased, but the slope was much lower than those of
16

colistin and ciprofloxacin (Figure 1-7 and Figure 1-8). Strains with high resistance to the
comparator antibiotics were not cross-resistant to CSA-13, suggesting that mechanisms of action
and of resistance are distinct. The increase in MIC values against CSA-13 appears to be due to
lipid A modifications. To confirm this hypothesis, lipid A modification in the LPS extraction
from the strain with resistance was tested.

Figure 1-7: Serial Passage A. baumannii
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Figure 1-8: Serial Passage P. aeruginosa

Lyophilized bacterial cells were vigorously vortexed in chloroform. Then, cells were
centrifuged to separate solids. The aqueous phase was lyophilized. LPS was further purified by
adding MgCl2 solution. The resulting mixture was centrifuged. The solid was washed with a
mixture of chloroform and methanol.

Lipid A was obtained as a precipitate after being

centrifuged. Then, detergent was added to hydrolysis LPS. After lyophilization, the detergent
was removed using diluted HCl in ethanol. After being dried, the residue was considered to be
pure lipid A. MALDI-TOF was used to chactarize the lipid At. For the wild type of lipid A, the
mass was found to be 1617.90. As for the mutation, a mass of 1748.94 was observed together
with 1617.90 (Figure 1-9). The difference of 131 in Mass is aminoarabinose, which is also
found in bacteria resistant to AMPs.

18

Figure 1-9: The mass spectra of the wild type lipid A and the mutation

1.2.3 Results and discussion
For the bactericidal activity of CSA-13, there is a large electric potential across the
cytoplasmic membrane of bacteria.

This electrical barrier can be dissolved through a

perturbation of the membrane, which would allow the flow of charge without necessarily
allowing the passage of small organic molecules such as ONPG. Due to the fact that results from
the assays with E. coli ML-35p indicated that not all the CSAs achieved bactericidal activity by
increases in the rate of transport of molecules across the cytoplasmic membrane, we investigated
that there was a smaller breach of the permeability barrier of the cytoplasmic membrane that
would allow passage of electrical current, perhaps as a result of proton flux, causing membrane
depolarization without allowing passage of larger molecules. DiS-C2(5), a kind of fluorescent
cyanine dye was used to monitor membrane depolarization. In the experiment, CSA-13 can
19

efficiently depolarize the cytoplasmic membrane of Gram-negative bacteria and induce solute
leakage, causing a bactericidal effect.
For the bacterial resistance against CSA-13, the MICs of Gram-positive bacteria grew
slightly. The resistance of Gram-negative bacteria against CSA-13 increased obviously, but not
as significantly as that of other antimicrobial agents. Besides, the resistance is not mutated to the
bacteria genes, and fades away without the presence of CSA-13. In Mass spectrum, structural
changes of lipid A in the mutation of the cell membrane were observed. Aminoarabinose was
found being added on the membrane surface.

1.3. Process Development of CSA-13
Due to the excellent antimicrobial activities of CSA families, many applications of CSA
are possible. Hence, to synthesize CSAs in large scale will be necessary. Two routes have been
developed from cholic acid or methyl cholate to CSA-13 in large scales.
In the original route (Scheme 1-1), sodium azide was used to replace the terminal
hydroxyl groups on the side chains. But for the industry synthesis, azide is not recommended
due to the explosion potency and the high toxicity. Hence, other routes or reagents to avoid
azide are necessary. Fewer steps and recrystallization instead of column purification are highly
desired. Two new routes have been investigated to fulfill those demands.

20

Scheme 1-1: The original route to synthesize CSA-13

1.3.1 Route 1
From cholic acid, LiAlH4 reduction gave the tetraol 1-3, in which the unreacted acid can
be washed off with MeOH. Additionally, after getting rid of water by heating, the product was
obtained as a powder. Trityl group was used to selectively protect the primary hydroxyl group in
21

acetonitrile with pyridine at 80°C for 12 hrs. Filtration afforded pure 1-4, and the by-product
remained in the solvent. Heating of the product powder was used to remove the trace amount of
the solvent. The yield was 92%. Allylation, followed by hydroboration, produced 1-6 in up to
90% yield after recrystallization (Scheme 1-2).

Scheme 1-2: The optimized synthesis of intermediate 1-6

1-6 was then dissolved in methyl ethyl ketone.

After mesylation, followed by

substitution by potassium phthalimide, 1-7 can be obtained in nearly quantitive yield. Removing
the trityl protecting group and recrystallization gave 1-8 in 88% yield. Mesylation, followed by

22

octylamine substitution at room temperature afforded crude 1-9. Hydroxylation using KOH in
EtOH produced crude CSA-13 (Scheme 1-3).

Scheme 1-3: The optimized synthesis of CSA-13 from 1-6

With a large amount of CSA-13 and the derivatives in hand, we are able to investigate
their activities and behaviors in vivo.

1.3.2 Route 2
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The key step in CSAs synthesis is to install the three carbon side chains on cholic acid
and derivatives. Previously, only allyl halides were found to react with three hydroxyl groups in
the steroid nucleus. Other electrophiles, such as acrylate, acrylamide and acrylonitrile, failed to
sufficiently react with the oxygens at 3, 7 and 12 position due to the high hindrance at those
positions and polymerization of the agents under basic conditions.
An ether transformation method has been reported by Marcel Schlaf.41 Butyl vinyl ether
was used to install a vinyl group on a alcohol and release butanol as a by-product (Scheme 1-4).
This reaction was carried out using palladium acetate as catalyst under basic condition. If we
can build vinyl groups on the hydroxyl groups, then, metathesis can be used to grow up the side
chain.

Scheme 1-4: The mechanism of the ether transformation

Three equivalents of palladium catalyst and butyl vinyl ether were then tried to transfer
vinyl group on methyl cholate, followed by metathesis to install three carbon side chains with
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terminal nitrogen on the scaffold. The hindrance on the 12 position caused the low yield of the
intermediate (Scheme 1-5), so that the strategy was abandoned.

Scheme 1-5: Applied transvinylation on installing three-carbon side chain.

Then, we tried to synthesize 1-1 using 3-methoxy acrylonitrile to do transvinylation
directly with methyl cholate. The yield surprisingly reached 80%, but unfortunately, it’s not
reproducible. We think the reaction system must be contaminated and the unknown compound
promotes the desired result. So, a series of reactions conditions were investigated (Scheme 1-6).

Scheme 1-6: Synthesis of 1-1
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To get a consistent high yield, we tried different amounts of palladium catalyst and base.
We found that the yield is not related to the amount of catalyst, nor that of base. Raising the
reaction temperature and pumping methanol out of the reaction system helped increase the yield.
The following mechanism was proposed (Scheme 1-7). The hydroxyl group attacks the
unsaturated nitrile to do 1, 4-addition. Then, the lone pair electrons on the nitrogen push back to
reform the conjugated nitrile, and an equivalent of methanol is generated. Pulling off the
methanol from system by connecting the reaction system with lab vacuum helps in improving the
yield.

Scheme 1-7: Proposed mechanism of ether transfer on 3-methoxy-acrylonitrile under basic condition

Based on the hypothesis, the reaction should work better under acidic conditions. It is
possible that iodide could also help. As a result, different amounts of NaI and acids were then
added, instead of base and .palladium catalyst (Scheme 1-8). Under acidic condition, iodide
undergoes a 1, 4-addition, followed by the removal of methanol, generates the vinyl iodide.
Then, the hydroxyl group on the substrate replaces the iodide by the same route to produce the
product.
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Scheme 1-8: Proposed mechanism of ether transfer on 3-methoxy-acrilonitrile under acidic condition

These series of experiments showed that 0.25 equivalent of TsOH and 0.1 equivalent of
NaI gave the best yield (Scheme 1-9). PPTS was also tried, but it produced a significant amount
of unknown by-product. With the optimized method, the reaction was applied in a large scale,
with a 97% yield. A 100g scale of methyl cholate was tried and the conditions worked well.

Scheme 1-9: Optimized method to install the side chains on methyl cholate

From compound 1-1 to CSA-8, there were three double bonds, three nitriles and one ester
that needed to be reduced (Scheme 1-10). For the global reduction, seven equivalents of BH3
were used in the next step to drive the reaction to completion, but the yield was disappointing.
Less than 10% of the product was isolated. LAH reduction was also tried, but no product was
observed. A strong mass peak of 1-3 showed up in the spectrum.
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Scheme 1-10: Preparation of CSA-8 from 1-1

β-elimination is considered to be the main issue (Scheme 1-11). By monitoring the
reaction using mass spectrometry, reduction of the double bonds was first observed. Since the αproton on the saturated nitrile, formed in the hydride 1, 4-addition, is acidic, it could be pulled
off by the base in the system, and the lone pair electrons should be able to eliminate the βoxygen to generate alkoxides.

Scheme 1-11: β-elimination of the saturated nitrile intermediate

As a result, to get a better yield, the smallest amount BH3 was used (Scheme 1-12).
Hydrogenation was preformed to reduce the three double bonds; consequently we could use 3
less equivalent of BH3 to get all the functional groups reduced. However, the hydrogenation
proceeded slowly, even after 20% palladium on carbon was used in MeOH at 100 psi of the
hydrogen. Acetic acid was not helpful, due to β-elimination. The reaction would not complete
in two weeks. In order to reduce the nitrile and ester, four equivalent of BH3 was used. After
refluxing for five hours, the nitrile groups were converted to free amines, and the yield rose to
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20%, from 1-1 to CSA-8. NaBH4 reduction catalyzed by NiCl2 or CoCl2 was also performed,
but no product could be detected.

Scheme 1-12: Optimized synthesis of CSA-8 from 1-1

Further hydrogenation catalyzed by Raney Ni was pursued under acidic conditions to
prevent amine ester exchange. There was almost no product detected. β-Elimination seemed to
be the major issue by mass spectrometry. Considering the components in Raney Ni, we removed
the NaOH by washing the catalyst using H2O and MeOH, sequentially. However, the reaction
did not proceed under this condition (Scheme 1-13).

29

Scheme 1-13: Failed hydrogenation using Raney Ni

Considering that free amine will react with Boc2O and release CO2 and iso-butene, three
equivalent of Boc2O was added in the reaction system. The hydrogenation completed in one day
and the formed amine was protected with Boc in situ. The intermediate was used in the next step
without purification. Borane reduction afforded Boc-CSA-8 in 50% yield for 3 steps (Scheme 114).

Scheme 1-14: Optimized preparation of Boc-CSA-8 from 1-2.
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Mesylation, followed by octylamine substitution, produced Boc-CSA-13.

After

purification, Boc-CSA-13 was deprotected under acidic conditions, and pure CSA-13, HCl salt,
was obtained without purification. The synthesis was finished in 6 steps, and the yield is 43.65%
(Scheme 1-15).

Scheme 1-15: Synthesis of CSA-13 from Boc-CSA-8

1.4 Development of ceragenins derivatives and the applications
1.4.1 99mTc binded CSA derivatives in cell imaging
1.4.1.1 Medical imaging
Medical imaging is a technique using radionuclides to create image of the body for
clinical purposes. It relies on the process of radioactive decay in the diagnosis and treatment of
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disease.42

Radionuclides are combined with existing pharmaceutical compounds, to form

radiopharmaceuticals. These radiopharmaceuticals can localize to specific organs or cellular
receptors, once applied to the patient. This property of radiopharmaceuticals allows nuclear
medicine to image the extent of a disease-process in the body, based on the cellular function and
physiology, rather than relying on physical change by the tissue surgery. In some cases, nuclear
medicinal studies can identify medical problems on an earlier stage than other diagnostications.

1.4.1.2 99mTc
99m

Tc is a metastable nuclear isomer of

99

Tc. It has a 6 hour half-life which is much

shorter than most of nuclear isomers that undergo γ-decay. In 24 hours, 93.7% of it decays to
ground state 99Tc, and the wavelength of the emitted γ-ray is about the same as conventional Xray diagnostic equipment. The short half life of the isotope allows for rapid data collection and
keeps patient radiation exposure low. Hence, 99mTc is widely used in medical imaging.43

1.4.1.3 CSA derivative used in medical imaging as 99mTc binder.
Since CSAs have a high binding affinity with prokaryotic membranes over eukaryotic
membrane, due to anionic PG and CL in cell membrane components, CSAs should be able to
bring the radioactive elements, bound to them, to the bacteria infected organs or parts of the
human body.
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In our research, we designed CSA-107 to achieve that purpose (Figure 1-10). Literatures
reports indicate that using aminothiol to chelate 99mTc produced a relatively stable complex.n In
CSA-107, we added similar functional groups on the 24 position of the CSA scaffold.

Figure 1-10: Structure of CSA-107

First, Boc-protected-CSA-8 was used as starting material. Mesylation followed by 3aminopropanol substitution produced 1-11. Boc-protection followed by Dess-Martin oxidation
gave the corresponding aldehyde 1-12. Reductive amination with diethanolamine produced 1-13
(Scheme 1-16).
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Scheme 1-16: Synthesis of intermediate 1-13

Mesylation followed by potassium thioacetate substitution generated 1-14.

Boc-

deprotection under acidic condition followed by LiOH hydroxylation failed to produce CSA-107.
The amino groups was freed by LiOH would attack the thioacetate to form the corresponding
amide. Removing acetyl group from the thioacetate, followed by deprotecting the Boc groups
afforded target CSA-107 (Scheme 1-17).
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Scheme 1-17: Synthesis of CSA-107

1.5 Experiment Section

To a solution of methyl cholate (50 g, 118 mol) in 800 mL of 3-methoxy-acrylonitrile,
PTS (3.5 g, 19.2 mmol) and NaI (700 mg, 4.7 mmol) were added. The mixture was heated to
80 °C under lab vacuum 1 day. The solvent was removed by distillation under vacuum. 66 g of
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the product was isolated, as a foam, through a column chromatography (SiO2). The yield was
97%.

To a solution of the 1-1 (65 g, 123 mmol) in 300 mL of MeOH, 15 g of Pd(OH)2 was
added. The mixture was stirred 3 days under 1000 psi of H2. After filtration, the solvent was
removed and the residue was used in the next step without further purification. 1H NMR (CDCl3,
500 MHz) δ 3.724-3.797 (m, 4 H), 3.656-3.686 (m, 4 H), 3.359-3.404 (m, 3 H), 3.179 (br, 1 H),
2.569-2.706 (m, 7 H), 1.996 (q, J = 7.5 Hz, 2 H), 1.651 (s, 3 H), 1.388-1.416 (m, 2 H), 1.2681.313 (m, 10 H), 0.881 (t, J = 7.5 Hz, 3 H); 13C NMR (CDCl3, 125 MHz) δ 136.58, 40.10, 27.77;
HRMS (ESI) calcd for C12H24O [M+H]+: 184.1827, found: 184.1836.

To a solution of 65 g of crude 1-2 in 600 mL of THF, 400 mL of 1 M BH3 in THF was
added. The solution was reflux for 6 hrs. After the solvent was removed, 14 g of CSA-8 was
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isolated through a column chromatography (SiO2). The yield was 21%. 1H NMR (CDCl3 / 30%
CD3OD, 300 MHz) δ 4.43 (bs, 7 H), 3.74-3.68 (m, 1 H), 3.66-3.60 (m, 1 H), 3.50-3.57 (m, 5 H),
3.25-3.34 (m, 2 H), 3.06-3.17 (m, 2 H), 2.74-2.84 (m, 6 H), 2.01-2.19 (m, 3 H), 0.96-1.97 (m, 27
H), 0.94 (d, J = 7.2 Hz, 3 H), 0.92 (s, 3 H), 0.69 (s, 3 H); 13C NMR (CDCl3, 75 MHz) δ 80.44,
79.27, 75.77, 66.59, 66.53, 65.86, 62.51, 46.21, 45.84, 42.55, 41.53, 40.09, 39.43, 39.31, 39.02,
35.16, 34.93, 34.86, 34.57, 32.93, 32.71, 31.57, 28.66, 28.33, 27.64, 27.22, 23.04, 22.40, 22.29,
17.06, 11.98; HRMS (ESI) calcd for C10H17ISi [M+H]+: 566.4889, found: 566.4898.

To a solution of the 1-2 (65 g, 123 mmol) and Boc2O (88.7 g, 406 mmol) in 500 mL of
MeOH, 15 g of Raney Ni was added. The mixture was stirred 3 days under 1000 psi of H 2.
After filtration, MeOH was removed and toluene was used to help remove the water. The
residue was used in the next step without further purification.

1

H NMR (CDCl3, 500 MHz) δ

3.724-3.797 (m, 4 H), 3.656-3.686 (m, 4 H), 3.359-3.404 (m, 3 H), 3.179 (br, 1 H), 2.569-2.706
(m, 7 H), 1.996 (q, J = 7.5 Hz, 2 H), 1.651 (s, 3 H), 1.388-1.416 (m, 2 H), 1.268-1.313 (m, 10 H),
0.881 (t, J = 7.5 Hz, 3 H);

13

C NMR (CDCl3, 125 MHz) δ 136.58, 40.10, 27.77; HRMS (ESI)

calcd for C12H24O [M+H]+: 184.1827, found: 184.1836.
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From CSA-8: To a solution of CSA-8 (14 g, 24.8 mmol) in 200 mL of THF, Boc2O (18 g,
81.6 mmol) was added in portion. The solution was stirred overnight. 20.5 g of the product was
isolated through a column chromatography (SiO2)

From 1-3: To a solution of 54 g of crude 1-3 in 500 mL of THF, 200 mL of 1 M BH3 in
THF was added. The solution was stirred at room temperature for 24 hrs. After the solvent was
removed, 24 g of CSA-8 was isolated through a column chromatography (SiO2). The overall
yield was 50%.

To a solution of Boc-CSA-8 (20.5 g, 23.7 mmol) in 200 mL of THF, MsCl (2.98 g, 26.1
mmol) and Et3N (2.64 g, 26.1 mmol) were added at 0 °C. The temperature was allowed to rise
up to room temperature. The solution was stirred for 30 mins. Then, 100 mL of water was used
to wash the solution. The aqueous layer was extracted with DCM three times. The combined
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organic layer was dried over Na2SO4. After the solvent was removed, 50 mL of octylamine was
added to dissolve the residue. The mixture was stirred at 80 °C overnight. The temperature was
cooled to room temperature then, 200 mL of water and 200 mL of DCM were added. The
aqueous layer was extract with DCM three times and the combined organic phase was dried over
Na2SO4. After removing the solvent, 19.32 g of the product was isolated through a column
chromatography (SiO2). The yield was 85%.

To a suspension of LiAlH4 (9 g, 236.8 mmol) in 1 L of THF, cholic acid (50 g, 122.5
mmol) was added at 0 °C. The mixture was refluxed 24 hrs. 120 mL of saturated Na2SO4 was
added to quench the reaction at 0 °C. The filter cake was washed with 100 mL of cold MeOH.
42 g of 1-3 was obtained as a white powder, after the trace amount of water was removed under
120 °C. The yield was 95%. 1H NMR (CDCl3 / 30% CD3OD, 200 MHz) δ 3.98 (br, 1 H), 3.83
(br, 1 H), 3.60-3.46 (m, 2 H), 3.38 (br, 5 H), 2.30-2.10 (m, 2 H), 2.05-1.05 (m, 22 H), 1.03 (br, 2
H), 0.92 (s, 3 H), 0.71 (s, 3 H); 13C NMR (CDCl3, 50 MHz) δ 73.89, 72.44, 68.99, 63.51, 48.05,
47.12, 42.49, 40.37, 39.99, 36.62, 36.12, 35.58, 35.40, 32.77, 30.69, 30.04, 29.02, 28.43, 27.27,
23.96, 23.08, 18.00, 13.02; HRMS (ESI) calcd for C24H42O4 [M+H]+: 566.4889, found:
566.4898.
39

To a suspension of 1-4 (42 g, 106.5 mmol) in 400 mL of MeCN, TrCl (41.5 g, 149 mmol)
and dry pyridine (12.6 g, 159.75 mmol) was added. The suspension was heated at 65 °C for 16
hrs. After the temperature was cooled down to room temperature, 240 mL of MeCN was added.
The mixture was stirred for 2 hrs. The solid was washed with 100 mL of MeCN. 61 g of 1-4
was obtained as a white powder, after the trace amount of the solvent was removed under 120
°C. The yield was 92%. 1H NMR (CDCl3, 200 MHz) δ 7.46-7.42 (m, 6 H), 7.32-7.17 (m, 9H),
3.97 (br, 1 H), 3.83 (br, 1 H), 3.50-3.38 (m, 1 H), 3.01 (br, 1 H), 2.94 (dd, J = 14.2, 12.2 Hz, 2
H), 2.64 (br, 1 H), 2.51 (br, 1 H), 2.36-2.10 (m, 2 H), 2.00-1.05 (m, 22 H), 0.96 (d, J = 5.8 Hz, 3
H), 0.87 (s, 3 H), 0.64 (s, 3 H);

13

C NMR (CDCl3, 50 MHz) δ 144.77, 128.93, 127.91, 127.01,

86.43, 73.35, 72.06, 68.66, 664.28, 47.47, 46.53, 41.74, 41.62, 39.64, 35.57, 35.46, 34.91, 34.82,
32.40, 30.55, 28.21, 27.69, 26.80, 26.45, 23.36, 22.59, 17.83, 12.61; HRMS (ESI) calcd for
C43H56O4 [M+H]+: 637.4179, found: 637.4183.
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To a solution of 1-5 (41.5 g, 65.2 mmol) in 400 mL of dry THF, NaH (8 g, 326 mmol),
tetrabutylammonium iodide (802.4 mg, 2.17 mmol), and allyl bromide (39.4 g, 326 mmol) were
added. The mixture was refluxed overnight. 20 mL of MeOH was added to quench the reaction
at 0 °C. After the solvent was removed, 100 mL of water was added. Hexanes were used to
extract the mixture. The combined organic layer was dried over Na2SO4. After the solvent was
removed, 44.4 g of the crude product was obtained and used in the next step directly. 1H NMR
(CDCl3, 200 MHz) δ 7.48-7.30 (m, 6 H), 7.32-7.14 (m, 9H), 6.04-5.80 (m, 3 H), 5.36-5.04 (m, 6
H), 4.14-3.94 (m 4 H), 3.74 (dt, J = 13.8, 5.8 Hz, 2 H), 3.53 (br, 1 H), 3.20-2.94 (m 3 H), 3.31
(br, 1 H), 2.38-1.90 (m, 4 H), 1.90-0.96 (m, 20 H), 0.90 (d, J = 5.4 Hz, 3 H), 0.89 (s, 3 H), 0.64
(s, 3 H); 13C NMR (CDCl3, 50 MHz) δ 144.83, 136.27, 136.08, 128.94, 127.90, 126.98, 116.46,
115.40, 86.42, 80.94, 79.29, 74.98, 69.52, 69.39, 68.86, 64.39, 46.51, 46.42, 42.67, 42.14, 39.92,
35.63, 35.51, 35.13, 32.45, 28.98, 28.09, 27.66, 27.57, 26.72, 23.32, 23.11, 17.92, 12.69; HRMS
(ESI) calcd for C52H68O4 [M+H]+: 757.5118, found: 757.5123.
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To a 100 mL of 1 M BH3 in THF, cyclohexene (16 g, 200 mmol) in 50 mL of THF was
added 0 °C. The mixture was stirred 30 mins. 1-6 (22 g, 30 mmol) in 200 mL of THF was
added, and the solution was refluxed for 6 hrs. After the temperature was cooled down to 0 °C,
70 mL of 20% NaOH and 70 mL of H2O2 was added dropwise.carefully. The reaction mixture
was refluxed overnight. Before the THF was removed, KI / starch test paper was used to make
sure that no peroxide remained. EtOAc was used to extract the mixture and after dried over
Na2SO4, the solvent and the cyclohexanol were removed under vacuum. The resulting sticky oil
was used in the next step without purification. The crude yield was 90%. 1H NMR (CDCl3, 200
MHz) δ 7.50-7.42 (m, 6 H), 7.32-7.14 (m, 9H), 3.90-3.65 (m, 13 H), 3.50 (br, 6 H), 3.40-2.96 (m
6 H), 2.30-0.94 (m, 30 H), 0.90 (s, 3 H), 0.88 (d, J = 5.4 Hz, 3 H), 0.64 (s, 3 H);

13

C NMR

(CDCl3, 50 MHz) δ 144.73, 128.88, 127.85, 126.94, 86.36, 80.52, 78.90, 76.36, 66.82, 66.18,
65.77, 64.22, 61.53, 61.41, 61.34, 46.89, 46.04, 42.60, 41.59, 39.60, 35.37, 35.27, 34.88, 32.75,
32.44, 32.31, 28.82, 27.65, 27.48, 27.13, 26.77, 23.35, 22.74, 22.38, 18.08, 12.48; HRMS (ESI)
calcd for C52H74O7 [M+H]+: 811.5435, found: 811.5440.
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To a solution of crude 1-7 in 100 mL of THF, MsCl (3.8 g, 33 mmol) and Et3N (3.4 g,
33.5 mmol) were added at 0 °C. The solution was stirred for 30 mins. After removing the
solvent, 50 mL of water was added. The mixture was extracted with EtOAc. The combined
organic phase was dried over Na2SO4. After the solvent was removed, 100 mL of 2-butanone
was used to dissolve the residue. Potassium phthalimide (18.6 g, 100 mmol) was added, and the
mixture was stirred at 80 °C for 24 hrs. The product was obtained by recrystlization in 99%
yield. 1H NMR (CDCl3, 200 MHz) δ 7.50-7.42 (m, 6 H), 7.32-7.14 (m, 9H), 3.90-3.65 (m, 13
H), 3.50 (br, 6 H), 3.40-2.96 (m 6 H), 2.30-0.94 (m, 30 H), 0.90 (s, 3 H), 0.88 (d, J = 5.4 Hz, 3
H), 0.64 (s, 3 H);

13

C NMR (CDCl3, 50 MHz) δ 144.73, 128.88, 127.85, 126.94, 86.36, 80.52,

78.90, 76.36, 66.82, 66.18, 65.77, 64.22, 61.53, 61.41, 61.34, 46.89, 46.04, 42.60, 41.59, 39.60,
35.37, 35.27, 34.88, 32.75, 32.44, 32.31, 28.82, 27.65, 27.48, 27.13, 26.77, 23.35, 22.74, 22.38,
18.08, 12.48; HRMS (ESI) calcd for C52H74O7 [M+H]+: 811.5435, found: 811.5440.
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Route 1: Boc-CSA-13 (19.32 mg, 20 mmol) was dissolved into 50 mL of 4 M
HCl/Dioxane solution. The solution was stirred overnight. After removing the solvent, 200 mL
of toluene was poured into the residue. 13.5 g of CSA-13 was obtained by azeotropic removing
the solvent in 92% yield.

Route 2: To a solution of 1-9 in mL of DMF, 10 g of hydrozine was added. The mixture
was stirred at 80 °C 24 hrs. The mixture was poured into 100 mL of water and extracted with
hexanes 10 times. The yield was 77%.

To a solution of Boc-CSA-8 (500 mg, 0.58 mmol) in 5 mL of DCM, MsCl (73 mg, 0.64
mmol) and Et3N (64.5 mg, 0.64 mmol) were added at 0 °C. The temperature was allowed to rise
up to room temperature. The solution was stirred for 30 mins. Then, 2 mL of water was used to
wash the solution. The aqueous layer was extracted with DCM three times. The combined
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organic layer was dried over Na2SO4. After the solvent was removed, 3-amino-1-propanol (368
mg, 5 mmol) was added to dissolve the residue. The solution was stirred at 80 °C for 2 hrs. 3amino-1-propanol was removed under vaccum. 5 mL of water was used to wash the solution.
The aqueous layer was extracted with DCM three times. The combined organic layer was dried
over Na2SO4. After removing the solvent, the residue was dissolved into 5 mL of DCM. Then,
Boc2O (127 mg, 0.58 mmol) was added. The solution was stirred overnight. 480 mg of the
product 1-10 was isolated through a column chromatography (SiO2) in 92 yield%.

To a solution of 1-11 (650 mg, 0.67 mmol) in 2 mL of MeOH, amine (85 mg, 1 mmol),
NaBH(OAc)3 (120 mg, 1.38 mmol) and a drop of AcOH were added. The mixture was stirred at
50 °C overnight. After removing the solvent, the product was obtained through a column
chromatography (SiO2), in 82% yield.
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To a solution of 1-12 (500 mg, 0.58 mmol) in 5 mL of DCM, MsCl (73 mg, 0.64 mmol)
and Et3N (64.5 mg, 0.64 mmol) were added at 0 °C. The temperature was allowed to rise up to
room temperature. The solution was stirred for 30 mins. Then, 2 mL of water was used to wash
the solution. The aqueous layer was extracted with DCM three times. The combined organic
layer was dried over Na2SO4. After the solvent was removed, KSAc (368 mg, 5 mmol) was
added and the mixture was stirred overnight. After the solvent was removed, the product was
obtained through a column chromatography (SiO2) in 78% yield.

To a solution of 1-13 in MeOH, LiOH was added. The mixture was stirred 2 hrs. The
solvent was removed, and DCM was added. Saturated NH4Cl was used to wash the mixture.
The organic layer was dried over Na2SO4.
overnight.

TFA was added, and the solution was stirred

After the solvent was removed, the product was obtained through a column

chromatography (SiO2) in 69% yield.

1

H NMR (CDCl3, 500 MHz) δ 3.449-3.657 (m, 6 H),

3.086-3.230 (m, 9 H), 2.424-2.902 (m, 16 H), 1.678-2.055 (m, 18 H), 1.200-1.462 (m, 10 H),
1.019 (br, 1 H), 0.879-0.902 (m, 7 H), 0.638 (s, 3 H);

13

C NMR (CDCl3, 125 MHz) δ 136.58,

40.10, 27.77; HRMS (ESI) calcd for C40H79N5O3S2 [M+H]+: 742.5624, found: 742.5630.
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Chapter 2. Natural Killer T cells Recognize Glycolipids as Antigens

2.1 Introduction
2.1.1 Immune systems
An immune system within an organism is a system of biological structures and processes
that protects against disease by detection and killing of pathogens. The immune system protects
organisms from infection with layered defenses of increasing specificity. In nearly all forms of
life, the innate immune system can respond first to the evasion of pathogens. The innate immune
system’s response is non-specific and immediate, but no immunological memory is produced.1
If pathogens evade the innate immune system, vertebrates adopt the second layer of protection,
the adaptive immune system. The responses of adaptive immune system toward pathogens are
specific and can be retained in the form of immunological memory even after the pathogens have
been eliminated.2
The cells of the adaptive immune system are special types of leukocytes, called
lymphocytes. The two major types of lymphocytes are B cells and T cells, both are derived from
hematopoetic stem cells in the bone marrow.3 B cells and T cells both carry receptor molecules
that make them able to respond to specific targets. T cells recognize a “non-self” target, such as
a pathogen. The recognition requires antigens (small fragments of the pathogen) to be processed
and presented in combination with a “self” receptor called a major histocompatibility complex
(MHC) molecule.
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2.1.2 NKT cells
Natural killer T cells (NKT cells) are a special kind of lymphocyte that bridge the
adaptive immune system with the innate immune system. Studies have shown that diminished
numbers of NKT cells in human have been potentially relevant to various disease states. 4 An
increased incidence of autoimmune diseases including type 1 diabetes and rheumatoid arthritis
have been correlated with diminished numbers of NKT cells. Stimulation of NKT cells can
influence forms of lupus and generates positive outcomes in viral, bacterial and parasitic
infections. Even some human cancers have been correlated with a loss of NKT cells, and
stimulation of NKT cells leads to decrease in tumor size and growth. Due to the critically
important impact of NKT cells on human health, people have put great efforts trying to
understand the function of NKT cells in regulating immune responses.
NKT cells have been subdivided into at least three subsets.5 Among these the most
populous and well studied are referred to as invariant NKT cells (iNKT cells). This type of NKT
cells present a T cell receptor (TCR) made up of Vα14 subunit in mice and the Vα24 subunit in
humans. Through work by multiple research groups, it has been established that NKT cell
stimulation is mediated by presentation of glycolipids by CD1d to NKT cells.6 CD1d is one of a
family of glycolipid presentation proteins that are evolutionarily related to antigen-presentation
proteins major histocompatibility complexes (MHC) which are known to present peptides.

2.1.3 Cytokine release by NKT cells
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Upon stimulation, NKT cells can rapidly release a variety of cytokines, which are small
cell-signaling protein molecules. These cytokines can promote two different types of immune
responses.

One type of cytokine including interferon- (IFN-) and interleukin-2 (IL-2),

considered T helper 1 (Th1) cytokines, cause an inflammatory response. The other type of
cytokines includes IL-4 and IL-10, and they result in an immunomodulatory or Th2 response.
Inflammatory Th1 responses are effective in controlling bacterial, parasitic, and viral infections
and can even result in immune responses to tumors. However, Th1 responses also cause
autoimmune diseases including multiple sclerosis, lupus, rheumatoid arthritis and type I
diabetes.6 Th2 cytokines play a contrary role to the immunostimulatory properties of Th1
cytokines and their production can ameliorate autoimmune diseases. Since both Th1 and Th2
cytokines can be produced when the NKT cells are stimulated, optimum control of the types of
response generated are necessary for potential medicinal use. In order to treat infection and
tumors, a Th1 response is desirable. On the contrary, for prevention or inhibition of autoimmune
diseases, Th2 responses are targeted work by multiple groups has established that different
cytokine release profiles can be mediated by presentation of specific classes of glycolipids by
CD1d to NKT cells.7 Even relatively minor changes in glycolipid structure can result in large
affinity differences among the binding of CD1d loaded with glycolipid to NKT cell receptor, and
this affinity appears to impact the types of cytokines released by the cells.

2.1.4 Glycolipids as antigens
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The advances in the research on stimulation of NKT cells have resulted from the
discovery that α-galacotosylceramides possess distinct iNKT cell activating properties. During
the screening natural products for anti-tumor activites, six marine natural products, termed
agelasphins, were isolated from a sponge, Agelas mauritianus, by Koezuka etc in 1993. Those
compounds were found to prolong the life span of B16 mouse melanoma cells inoculated mice
and stimulated the proliferation of lymphocytes.8,

9

Among the agelasphins, agelasphin 9b

showed potent antitumor activities. In general, only glycosylceramides that have β-glycosidic
linkage are found in higher organisms.

Agelas mauritianus contains an α-glycosidic bond

between the sugar and ceramide, which is rare. The Kirin group first did structure-activity study
of various of agelasphin 9b.10 They synthesized a series of analogues of agelasphin 9b and found
the hydroxyl group at C2’ of ceramide (see Figure 2-1 for ceramide numbering) does not
significantly influence anti-tumor activity, and the C4 hydroxyl group plays a minor role, but the
hydroxyl group at C3 is necessary to maximize activity. Their result also demonstrated that the
branched phytosphingosine chain could be simplified into a straight-chain lipid and a longer acyl
chain tended to be more biologically active. Taking these findings into consideration; a more
potent compound KRN7000 was generated.

Figure 2-1. Structure of agelasphin 9b.
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Figure 2-2. Structure of KRN 7000.

The Taniguchi group attempted to develop a ligand which can specifically activate Vα14
NKT cells, and with this compound study the mechanisms of activation of iNKT cells.11 In their
study, 10 synthetic glycolipids were used as candidate Vα14 T cell receptor (TCR) ligands and
the proliferative responses of Vα14 NKT cells were measured as readout. The stimulation ability
of monoglycosylated ceramides were compared as following (Figure 2-3).

Figure 2-3. Structure of monoglycosylceramides and comparison of their propensity to
stimulate proliferation of NKT cells.
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In recognition that KRN7000 has relatively poor solubility in either organic or aqueous
solvents, our group has synthesized a series of modified α-GalCer in order to determine which
site on the sugar head can be modified without negatively influencing the interactions of
glycolipid-loaded CD1d with NKT cell receptors. We found that replacing the 6 hydroxyl group
of galactose in α-GalCer with an amide linked to a variety of small molecules yields the
compounds which retain the ability to stimulate NKT cells comparable to KRN7000.12 Further
studies optimized the structures and generated a new glycolipid PBS-57. PBS-57 has a small
acetamide group at C6 position of galactose and a cis-double bond in the acyl chain of the
ceramide portion. Especially, the cis-double bond in the acyl chain results in an increase of the
solubility over the fully saturated compounds and also facilitates the loading into CD1d tetramers.
In vitro and in vivo studies indicated that PBS-57 can stimulate NKT cells more effectively than
KRN7000.13

Figure 2-4. Structure of PBS 57.

A research aiming to investigate the recognition mode of Vα14i NKT toward the
glycosphingolipid antigens was conducted by Kronenberg group recently.14 The equilibrium
dissociation constant characteristic of the affinity of the Vα14i NKT TCR for the
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glycolipid/CD1d complex was measured. The affinity was found to correlate with the ranking of
the antigenic potencies of the α-GalCer related glycolipids(α-GalCer>4-deoxyα-GalCer>αGlcGer>αManCer). Binding was not detectable for β-GalCer and 3,4-deoxy α-GalCer analogues.
The above results demonstrate that the changes in the sugar part and modifications in the
ceramide part both have big impacts on the interactions among the three partners.

The

recognition of NKT cells comes from glycolipid interactions with CD1d and or the TCR. The
excellent glycolipid structure should be bound well by CD1d first and then the proper positioned
complex may be effectively recognized by the TCR.
As described above, the optimum control of the nature of the stimulation of NKT cells is
needed for different potential medicinal use. In 2001 Miyamoto and coworkers’ studied how the
altered structure of α-GalCer can cause the NKT cells to respond with a Th2 bias.15 They
synthesized three analogues of α-GalCer by changing the sugar moiety and /or truncating the
aliphatic chains (Figure 2-5). Through measuring the serum cytokine levels after injection of
these compounds, it was found that compound OCH could induce predominant production of IL4 by NKT cells while α-GalCer causes NKT cells to produce both interferon (IFN)-g and IL-4.
Although compared with α-GalCer OCH was less active in inducing cell proliferation, it could be
useful as a therapeutic agent to prevent against TH1 mediated diseases such as experimental
autoimmune encephalomyelitis.
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Figure 2-5. The structures of analogues of α-GalCer

Our group also investigated the impact of truncation of lipid chains on the response of
NKT cells.16 The results suggest that there is a correlation between lipid chain length and
cytokine release profiles, the chain-shortened glycolipids increase the amount of IL-4 relative to
INF-γ released by NKT cells. The results were consistent with the studies of Oki et al. 17 They
explained that truncation of the phytosphingosine chain of α-GalCer leads to a less stable
complex with CD1d and INF-γ release by NKT cells requires longer stimulation by CD1dglycolipid complexes than IL-4.

2.2 Thraustochytroside A and B
2.2.1 Background
Marine microorganisms have been well known as a new source of novel nature
products.18 The Fenical group examined a group of marine protists, the thraustochytrids which
were isolated from the surface of the tropical seagrass, Thalassia testudinum, collected in the
Bahamas Islands.19 They isolated one strain that produced a series of new glycosphingolipids.
Through HRMS, 1H NMR,

13

C NMR and 2D NMR, the new glycosphingolipids were
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characterized as thraustochytrosides A-C.

Thraustochytroside A had particular interesting

structure since it contains a fairly unusual tri-ene sphingosine lipid chain with a methyl branch at
C9 position. Compounds such as the ophidiacerebrosides,20 the agelasphins21 and marine GSLs
all show impressive bioactivities and they all contain this structural moiety.
As we described above, PBS-57 was found to be a very good NKT cell stimulator, and
the structure was developed after investigating the marine product, agelasphin 9b. Following
this idea, we want to synthesize thraustochytrosides and do further tests to see if their unique
structure will contribute the bioactivities.

2.2.2 Synthesis of Thraustochytroside B and the analog 2-36
The synthesis of the ceramide part of 2-12 starts from 1-decyne (Scheme 2-1).
Carbometalation followed by paraformaldehyde quenching the reaction generated 2-2. The
hydroxyl group was replaced by chloride to generate 2-3, in the presence of triphenyl phosphine
and NCS. 1-TMS propyne anion was used to substitute chloride and 2-4 was produced. TBAF
removed the TMS affording 2-5.

Scheme 2-1: Synthesis of 2-5

59

Boc protected serine was used as the other starting material (Scheme 2-2).

The

corresponding Weinreb amide was prepared and the intermediate was protected with
isopropylidine. LAH reduction gave Garner’s aldehyde. Reacting compound 2-5 with the
aldehyde produced 2-6.

Scheme 2-2: Synthesis of 2-6

Birch reduction conditions were used to convert the triple bond to a trans-double bond,
meanwhile, all the protecting groups were removed to afford 2-7 (Scheme 2-3). Reacting the
intermediate 2-7 with one equivalent of palmitic acid and EDCI produced compound 2-8.
Selective protecting the primary alcohol with TDS, followed by reacting the second hydroxyl
group with acetic anhydride, then removing the TDS afforded 2-9.
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Scheme 2-3: Synthesis of 2-9

Coupling ceramide 2-9 with 2-10 in the presence of TMSOTf gave 2-11 (Scheme 2-4).
Birch reduction conditions were used to remove all the protecting groups generating
Thraustochytroside B in 0.4% total yield for 12 steps.
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Scheme 2-4: Synthesis of Thraustochytroside B

After comparing the 1H NMR of the synthesized thraustochytroside-B with what was
reported by William Fenical, who did the isolation from the marine protist and characterization,
we found that the chemical shift of the proton on the 8th carbon did not match, but the 13C NMRs
were identical. The chemical shift in the literature was 5.10 ppm, and we measured 5.35 ppm.
We assumed that the author had obtained another compound from the isolation. We
suggested that the 19th methyl group connected with the 8th carbon. This meant that the sp2
proton was on the 9th carbon, instead of 8th carbon, which might change the environment of the
proton and make change the chemical shift. Hence, that led us to make 2-36.
(1-Ethoxycarbonylethyliden)-triphenylphosphoran was used as the starting material
(Scheme 2-5). Wittig reaction, followed by DIBAL reduction provided 2-27. Then, similar
procedures were used to prepare thraustochytroside-B.
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Scheme 2-5: Synthesis of 2-36

Unfortunately, the chemical shift on the 9th carbon was still around 5.35 ppm, which
meant that our assumption was not true. Interestingly, the corresponding chemical shift of
thraustochytroside-C located at 5.35, and the difference between the two compounds was only a
hydro-carbon on one of the lipid chain terminals, which was non-significant in the 1H NMR
spectrum. We thought 5.10 might be a typo. So we bought some thraustochytrides. From the
isolation, we found the compound whose 1H NMR was identical with what we synthesized, but
we didn’t find the compound as reported.

In summary, we think we did synthesize the

thraustochytroside-B with the right structure.

2.2.3 Approach Synthesis of Thraustochytroside A
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The approach to the synthesis of thraustochytroside-A started from 1-hydroxy-2-butyne.
Hydrostannation was designed to install a functional group on the C3 position and make the
oxygen cis to the methyl group (Scheme 2-6). Trityl group was first tried to protect the hydroxyl
group.

In our hypothesis, the protecting group was big enough to drive the tin reagent

approaching from the far terminal and get better ratio of 2-37. However, the ratio was not as
high as we expected. Only 60% yield of the desired region-isomer was isolated after several
columns, because the polarity of the other isomer was very similar to the product.

Scheme 2-6: Orginal route to 2-37

Hydroxyl group directed hydrostannation had been reported for successfully generation
trans-double bonds.28 This method also worked well with our substrate, and we were able to get
2-37 in 93% yield (Scheme 2-7). Stille coupling was used to generate the diene. Efforts to
functionalize the hydroxyl group on the hydroxyl diene failed, because the new generated
functional group easily went elimination and cyclization.
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Scheme 2-7: Failed efforts to generate 2-42

To prepare 2-42, 2-37 was converted to the corresponding iodide 2-38 (Scheme 2-8). 239 was obtained by adding Ph3P and NCS in THF. Substitution gave 2-40. For the Suzuki
coupling, (Ph3P)4Pd gave better yield than Pd2(dba)3 to generate 2-41. K2CO3 in methanol
removing TMS group afforded 2-42.

Scheme 2-8: Synthesis of 2-42.
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The reaction between 2-42 and Garner’s aldehyde worked well (Scheme 2-9). However,
simultaneously reducing and deprotecting the adduct failed due to the reduction of the diene
under Birch condition. One of the double bonds disappeared in NMR. Hence, we tried to
deprotect the Boc and isopropylidine first, but the deprotection using acidic condition led to the
hydrolysis of the conjugated double bond.

Scheme 2-9: Failed route to get the sphingocin derivative

Since the deprotection failed, another synthetic strategy was needed. Instead of using
Garner’s aldehyde, other protecting groups to protect the amino group and the primary hydroxyl
group were necessary (Scheme 2-10).

Scheme 2-10: Strategy change
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Considering the required reduction of the triple bond after the aldehyde addition, use of a
vinyl anion to react with an aldehyde would be more convergent. To get higher yields in the
sugar coupling, azide was used to protect the sphingosine amine.

To get the desired

configuration in the product, we had used Garner’s aldehyde because the addition followed the
Felkin-Ahn model due to the large size of the Boc-protecting group. Once small azide was used
to replace Boc, we had to consider chelation control. However, TBS protecting group is too big
for chelating the metal atom. Thus, tritheyl silyl group was chosen in the addition to protect the
primary alcohol (Figure 2-6).

Figure 2-6: Two types of Reaction Models

Methyl serine was used as the starting material (Scheme 2-11). Selective protecting the
primary alcohol using TBSCl generated 2-44 in nearly quantitive yield. LAH reduction gave 245. Azide transfer provided 2-46. The hydroxyl group was protected with Ac group. The TBS
was removed under slightly basic condition to give 2-48.
With 2-42 in hand, hydrozirconation or hydroboration, followed by iodionation provided
a mixture, which was hard to characterize (Scheme 2-11).
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Scheme 2-11: Synthesis of 2-48 and Failed route to the iodide intermediate

The future plan is shown in Scheme 2-12. TES will be used to protect the alcohol instead
of TBS group. Then, acetyl group can be removed under ammonia in MeOH. Dess Martin
oxidation should gave the desired aldehyde intermediate 2-43.
For the other part, with the boron intermediate, Suzuki coupling should generate the
corresponding tin intermediate 2-57 without any problem. After transmetallation, the lithium
agent will react with 2-43 to produce 2-58, and the stereoselectivity follows chelation control
rule, as we discussed above. After masking the secondary alcohol with TBS, TES will be
removed under slightly acidic condition to get 2-59. Coupling with 2-63, which is a known
compound, would give 2-60, and the α-stereoselectivity is preferred with TBS protection at sugar
C2 position. Staudinger reduction can convert the azide to amine group and amidation should
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produce 2-62 in high yield. The final step would be TBAF deprotection, and all the TBS group
would be removed to yield thraustochytroside A.
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Scheme 2-12: The future plan to synthesis thraustochytride A
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2.3 Asperamides A and B
2.3.1 Background
Since the 1990s, a large amount of novel bioactive metabolites have been discovered
from marine derived fungi.22 Recently Wang group isolated an endophytic fungus from marine
brown alga Colpomenia sinuosa and two new sphingolipids namely asperamides A and B were
characterized by spectroscopic and chemical methods.23 It is the first time that sphingolipids
isolated from marine algal-derived fungi containing 9-methyl-C20-sphingosine moiety were
isolated. In antifungal assays, the asperamides exhibited moderate activity against Candida
albicans.

Figure 2-7: Structure of Asperamides A and B
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Sphingolipids are widely distributed in the bacteria and almost all eukarytic organisms
and they have a variety of functions such as signal transduction, cell differentiation and
recognition of pathogens. Many sphingolipids have been proved to be potent medicial agents,
including antitumor, antifungal, antiviral, neuritogenic and immunoregulatory compounds.24-27
My research is aimed to explore novel medicinal important glycolipids mainly sphingolipids by
synthetic methods. In recognition that the thraustochytrosides and asperamides compounds all
share the interesting and novel sphingosine lipid chain with a methyl branch at 9th position and
unsaturated double bond at 8th position, we planned to synthesize the compounds and then test
and compare their bioactivity. We expected that the structurally interesting sphingosine lipids
would exhibit activities including stimulating NKT cells.

2.3.2 Synthesis of Asperamide A
The synthesis of the acyl chain on the ceramide started from the commercial available
(R)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde (Scheme 2-13). Schlosser-Wittig reaction gave
the trans-product 2-51. The isopropylidine was removed under acidic condition to yield 2-52.
The primary alcohol was selectively protected and the secondary hydroxyl group was masked
with benzoyl group to form 2-54. TBS was removed and the resulting alcohol was oxidized to
generate the corresponding acid 2-56.
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Scheme 2-13: Synthesis of the acyl chain on the ceramide

The synthesis of 2-25 started from tridec-1-yne.

The difference between the key

intermediate 2-18 and the amino diol 2-7 was the chain length of the hydrophobic end of the
compound. Thus, the same procedure to prepare 2-7 was used to synthesize the sphingosine 218 (Scheme 2-14).
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Scheme 2-14: Synthesis of the sphingosine

Azide transfer generated 2-19 (Scheme 2-15). After TDS selective protection, protecting
the secondary alcohol, followed by removing TDS with HF in THF produced 2-20. Coupling 220 with 2-21 gave 2-22. Triphenyl phosphine mediated reduction of the azide yielded the amine
2-23. Amidation gave intermediate 2-24. Global deprotection generated asperamides A, as a
mixture of diastereomers. Apparently, epimerization occurred at the C2’ position during the last
deprotection step. Sodium methoxide was acting as not only a neucleophile, but also a strong
base. So, for the new batch, we will use ammonia in methanol to do the global deprotection.
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Scheme 2-15: Synthesis of asperamide A
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2.4 Experimental section

To a stirred suspension of Cp2ZrCl2 (3g, 10 mmol) in 50 mL of dry THF, methyl
aluminium (20 mL, 2 M) in hexane was added dropwise at 0 °C. The temperature was allowed
to rise up to room temperature, then, the solvent was removed under vacuum. The residue was
dissolved into 40 mL of DCM and the solution was cooled to 0 °C. 1-decyne (3.6 mL, 20 mmol)
was then added dropwise under 0 °C. The solution was stired 1 hr at room temperature. The
reaction temperature was cooled back down to 0 °C. Paraformaldehyde (1.25 g, 40 mmol) was
added in four portions over 10 minutes. The solution was stirred for half an hour. Then, 10 mL
of MeOH was added dropwise carefully. After quenching the reaction, the solvent was removed
and the residue was extracted using ethyl acetate. 2.32 g of the product was isolated through a
column chromatography (SiO2) in 63% yield. 1H NMR (CDCl3, 500 MHz) δ 5.386 (t, J = 8.5 Hz,
1 H), 4.125 (d, J = 8.5 Hz, 2 H), 2.251 (br, 1 H), 1.996 (q, J = 7.5 Hz, 2 H), 1.651 (s, 3 H),
1.388-1.416 (m, 2 H), 1.268-1.313 (m, 10 H), 0.881 (t, J = 7.5 Hz, 3 H); 13C NMR (CDCl3, 125
MHz) δ 136.58, 40.10, 27.77; HRMS (ESI) calcd for C12H24O [M+H]+: 184.1827, found:
184.1836.
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To a solution of triphenyl phosphine (4.62 g, 17.6 mmol) in 50 mL of dry THF, NCS
(2.35 g, 17.6 mmol) was added at 0 °C. The resulting suspension was poured into 2.32 g of 2-2
at 0 °C. The temperature was allowed to rise up to room temperature. The suspension was
stirred for 5 hrs. Then, the solvent was removed and the brown residue was cracked and washed
with hexanes. The filtrate was collected and the solvent was removed. Then hexanes was used
to extract it, and after removing the solvent, the crude product was used in the next step without
any further purification.

To a solution of 1-TMS-1-propyne (3.76 mL, 25 mmol) in 50 mL of THF, n-BuLi (10
mL, 2.5 M) was added dropwise at -78 °C. The solution was stirred at -40 °C for 30 mins then,
cooled to -78 °C. 2-3, from the last step, was added dropwise, and the temperature was allowed
to rise up to room temperature. The solution was stirred overnight. Saturated NH4Cl was added
to quench the reaction. The mixture was extracted with hexanes and dried over Na2SO4. 2.8 g of
the product was isolated through a column chromatography (SiO2), in 79% yield.

1

H NMR

(CDCl3, 500 MHz) δ 5.146 (br 1 H), 2.205-2.236 (m, 4 H), 1.969 (t, J = 7.5 Hz, 2 H), 1.607 (s, 3
H), 1.268-1.396 (m, 14 H), 0.883 (t, J = 7.5 Hz, 3 H), 0.143 (s, 9 H);

13

C NMR (CDCl3, 125

MHz) δ 137.133, 122.524, 107.660, 84.378, 39.908, 32.169, 29.778, 29.572, 29.523, 28.152,
27.563, 22.932, 20.601, 16.243, 14.344, 0.348; HRMS (ESI) calcd for C18H34Si [M+H]+:
278.2430, found: 278.2438.
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To a calpis of 2-4 (2.8 g, 10 mmol) in 10 mL of MeOH, K2CO3 (1.38 g, 10 mmol) was
added. The mixture was stirred at room temperature overnight. The solvent was removed, and
the residue was extracted with hexanes. After removing the solvent, 2.1 g of the product was
isolated through a column chromatography (SiO2), in 99% yield. 1H NMR (CDCl3, 500 MHz) δ
5.171 (t, J = 7 Hz, 1 H), 2.190-2.245 (m, 4 H), 1.980 (t, J = 8 Hz, 2 H), 1.904 (t, J = 1 Hz, 1 H),
1.612 (s, 3 H), 1.267-1.397 (m, 12 H), 0.888 (t, J = 6.5 Hz, 3 H); 13C NMR (CDCl3, 125 MHz) δ
137.212, 122.421, 84.597, 68.288, 39.878, 32.176, 29.790, 29.602, 29.523, 28.127, 27.393,
22.938, 19.169, 16.171, 14.325; HRMS (ESI) calcd for C15H26 [M+H]+: 207.2035, found:
207.2041.

To a solution of 2-5 (1.9 g, 9.2 mmol) in 20 mL of dry THF, n-BuLi (10 mL, 2.5 M) was
added dropwise at -78 °C. The solution was stirred at -40 °C for 30 mins then, cooled to -78 °C.
Garner’s aldehyde (2.5 g, 11.4 mmol) was added. The solution was stirred overnight. Saturated
NH4Cl was added to quench the reaction. The mixture was extracted with DCM and dried over
Na2SO4. 2.6 g of the product was isolated through a column chromatography (SiO2), in 83%
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yield. 1H NMR (CDCl3, 500 MHz) δ 5.160 (t, J = 6.5 Hz, 1 H), 4.568 (d, J = 8.0 Hz, 1 H), 4.512
(d, J = 8.0 Hz, 1 H), 3.907-4.131 (m, 3 H), 2.288 (t, J = 7.5 Hz, 2 H), 1.959 (t, J = 6.5 Hz, 2 H),
1.587 (s, 3 H), 1.506-1.514 (m, 15 H), 1.263-1.327 (m, 12 H), 0.881 (t, J = 7.0 Hz, 3 H); HRMS
(ESI) calcd for C26H45NO4 [M+H]+: 436.3421, found: 436.3409.

To a blue solution of Li (230 mg, 32 mmol) in 10 mL of EtNH2, 2-6 (2.6 g, 6 mmol) in 5
mL of dry THF was added at -78 °C. The solution was stirred for 2 hrs. 2 g of NH4Cl was
added to quench the reaction. After the solvent was removed, the residue was extracted with
Et2O. The solution was dried over Na2SO4. The crude product was obtained as a clear glass, and
was used in the next step directly. The crude yield was 52%.

To a solution of palmitic acid (237 mg, 0.92 mmol) in 5 mL of THF, EDCI (191 mg, 0.93
mmol) and HOBT (125 mg, 0.93 mmol) were added. The solution was stirred for 30 mins, then,
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250 mg of compound 2-7 was added. The solution was stirred overnight at room temperature.
After removing the solvent, the product was used in the next step directly.

To a solution of 2-8 (310 mg, 0.58 mmol) in 2 mL of dry pyridine, TDSCl (155 mg, 0.87
mmol) was added. The solution was heated to 70 °C for half an hour. AcCl (54.6 mg, 0.7 mmol)
and DMAP (8.5 mg, 0.07 mmol) were added to the solution. After stirring for 1 hrs, the solvent
was removed. The residue was dissolved into 2 mL of THF. 5 mL of aqueous HF was added
and the solution was stirred for 1 hrs. The mixture was poured into 20 mL of saturated NaHCO3.
The mixture was extract with Et2O. 260 mg of the product was isolated through a column
chromatography (SiO2), in 77% yield.

1

H NMR (CDCl3, 500 MHz) δ 5.743-5.989 (m, 1 H),

5.635 (d, J = 8.5 Hz, 1 H), 5.426 (dd, J = 15.5, 7.0 Hz, 1 H), 5.246 (t, J = 5.5 Hz, 1 H), 5.082 (br,
1 H), 4.205 (br, 1 H), 3.761 (d, J = 8.5 Hz,1 H), 3.568 (dd, J = 8.5, 1 Hz, 1 H), 2.137 (t, J = 7.0
Hz, 4 H), 2.065 (s, 3H), 1.951 (t, J = 7.0 Hz, 4 H), 1.587-1.062 (m, 2 H), 1.576 (s, 3 H), 1.2541.315 (m, 18 H), 0.882 (t, J = 6.5 Hz, 3 H);

13

C NMR (CDCl3, 125 MHz) δ 166.027, 138.797,

136.921, 133.892, 130.360, 130.292, 129.044, 124.094, 123.407, 75.119,66.762, 62.517, 40.215,
33.151, 32.480, 30.211, 30.119, 29.902, 28.521, 27.686, 23.246, 16.544, 14.679; HRMS (ESI)
calcd for C36H67NO4 [M+H]+: 578.5070, found: 578.5074.
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To a solution of 2-10 (200 mg, 1 mmol) in 4 mL of CCl3CN, 160 mg of K2CO3 was
added. The solution was stirred overnight. After filtration, the solvent was removed. The
residue and 2-9 (160 mg, 0.27 mmol) were dissolved into 5 mL of dry DCM. 70 mg of active
4A molecular sieve was added. The mixture was stirred for half an hour. Two drops of
TMSOTf was added at 0 °C. The reaction was stopped by adding 100 μL of Et 3N after 2 hrs.
After filtration, the solvent was removed. 130 mg of the product was isolated through a column
chromatography (SiO2), in 13% yield.

1

H NMR (CDCl3, 500 MHz) δ 7.293-7.501 (m, 15 H),

6.110 (d, J = 9.0 Hz, 1 H), 5.792 (dt, J = 15.5, 7.5 Hz, 1 H), 5.543 (s, 1 H), 5.408 (dd, J = 15.5,
7.5 Hz, 1 H), 5.332 (t, J = 7.5 Hz, 1 H), 5.108 (t, J = 5.5 Hz, 1 H), 4.624-4.968 (m, 4 H), 4.185
(br, 1 H), 4.026 (t, J = 7.5 Hz, 1 H), 3.968 (dd, J = 7.5, 1.5 Hz, 1 H), 3.788-3.809 (m, 1 H), 3.654
(t, J = 7.5 Hz, 1 H), 3.587-3.605 (m, 2 H), 3.338 (dd, J = 7.5, 1 Hz, 1 H), 1.833-2.165 (m, 11 H),
1.587 (s, 3 H), 1.254-1.315 (m, 18 H), 0.882 (t, J = 6.5 Hz, 6 H); 13C NMR (CDCl3, 125 MHz) δ
172.973, 170.059, 138.778, 138.371, 137.594, 136.763, 134.208, 129.200, 128.782, 128.569,
128.472, 128.260, 128.199, 127.883, 127.750, 126.348, 125.425, 125.316, 101.718, 99.491,
82.533, 79.553, 78.794, 75.414, 74.188, 74.115, 69,235, 67.687. 63.008, 50.517, 39.204, 36.812,
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32.169, 31.320, 30.094, 29.954, 29.808, 29.693, 29.614, 29.493, 28.176, 25.918, 22.938, 14.374;
HRMS (ESI) calcd for C63H93NO9 [M+H]+: 1008.6850, found: 1008.6947.

To a blue solution of Na (23 mg, 1 mmol) in 5 mL of liquid NH3, 2-11 (50 mg, 0.05
mmol) in 1 mL of dry THF was added at -78 °C. The solution was stirred for 2 hrs. 2 g of
NH4Cl was added to quench the reaction. After the solvent was removed, the residue was
extracted with Et2O. 12 mg of the product was obtained through a column chromatography
(SiO2) in 34% yield. 1H NMR (CDCl3, 500 MHz) δ5.798 (dt, J = 15.5, 7.5 Hz, 1 H), 5.479 (t, J
= 10.0 Hz, 1 H), 5.341-5.434 (m, 2 H), 5.280 (t, J = 7.5 Hz, 1 H), 4.971-5.010 (m, 2 H), 4.886
(dd, J = 10.0, 4.0 Hz, 1 H), 4.347-4.381 (m, 1 H), 4.222 (dd, J = 7.5, 3.5 Hz, 1 H), 4.095 (dd, J =
7.5, 2.0 Hz, 1 H), 3.952-3.977 (m, 1 H), 3.720 (dd, J = 11.0, 7.5 Hz, 1 H), 3.540 (dd, J = 11.0, 3
Hz, 1 H), 1.833-2.165 (m, 6 H),, 1.587 (s, 3 H), 1.254-1.315 (m, 18 H), 0.882 (t, J = 6.5 Hz, 3 H);
13

C NMR (CDCl3, 125 MHz) δ 172.991, 170.490, 137.388, 131.531, 129.085, 1125.316, 96.748,

73.156, 70.722, 70.267, 69,035, 67.700. 62.025, 50.736, 37.080, 32.837, 32.606, 32.151, 29.469,
26.015, 22.914, 21.305, 20.923, 20.862, 14.338; HRMS (ESI) calcd for C40H75NO8 [M+H]+:
698.5493, found: 698.5500.
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To a stirred suspension of Cp2ZrCl2 (4.g, 13.85 mmol) in 50 mL of dry THF, methyl
aluminium (27 mL, 2 M) in hexane was added dropwise at 0 °C. The temperature was allowed
to rise up to room temperature, then, the solvent was removed under vacuum. The residue was
dissolved into 40 mL of DCM and the solution was cooled to 0 °C. 1-decyne (5 g, 27.7 mmol)
was then added dropwise under 0 °C. The solution was stired 1 hr at room temperature. The
reaction temperature was cooled back down to 0 °C. Paraformaldehyde (1.6 g, 54 mmol) was
added in four portions over 10 minutes. The solution was stirred for half an hour. Then, 10 mL
of MeOH was added dropwise carefully. After quenching the reaction, the solvent was removed
and the residue was extracted using ethyl acetate. 4.8 g of the product was isolated through a
column chromatography (SiO2) in 77% yield.

To a solution of triphenylphosine (7.8 g, 29.7 mmol) in 50 mL of dry THF, NCS (3.96 g,
29.7 mmol) was added at 0 °C. The resulting suspension was poured into 4.8 g of 2-13 at 0 °C.
The temperature was allowed to rise up to room temperature. The suspension was stirred for 5
hrs. Then, the solvent was removed and the brown residue was cracked and washed with
hexanes. The filtrate was collected and the solvent was removed. Then hexanes was used to
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extract it, and after removing the solvent, the crude product was used in the next step without any
further purification.

To a solution of 1-TMS-1-propyne (3.5 g, 31.5 mmol) in 50 mL of THF, n-BuLi (12.6
mL, 2.5 M) was added dropwise at -78 °C. The solution was stirred at -40 °C for 30 mins then,
cooled to -78 °C. 7 g of 2-14 was added dropwise, and the temperature was allowed to rise up to
room temperature. The solution was stirred overnight. Saturated NH4Cl was added to quench
the reaction. The mixture was extracted with hexanes and dried over Na2SO4. 6.8 g of the
product was isolated through a column chromatography (SiO2) in 65% yield for two steps.

1

H

NMR (CDCl3, 500 MHz) δ 5.171 (br, 1 H), 2.190 (br, 4 H), 1.980 (t, J = 8 Hz, 2 H), 1.612 (s, 3
H), 1.267-1.397 (m, 18 H), 0.888 (t, J = 6.5 Hz, 3 H), 0.143 (s, 9 H);

13

C NMR (CDCl3, 125

MHz) δ 132.419, 117.372, 79.837, 63.283, 34.879, 27.171, 24.894, 24.806, 24.600, 24.508,
23.143, 22.407, 17.933, 14.191, 0.348; HRMS (ESI) calcd for C18H32 [M+H]+: 321.2899, found:
321.2910.

To a calpis of 2-15 (4.5 g, 14 mmol) in 10 mL of MeOH, K2CO3 (1.9 g, 14 mmol) was
added. The mixture was stirred at room temperature overnight. The solvent was removed, and
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the residue was extracted with hexanes. After removing the solvent, 3 g of the product was
isolated through a column chromatography (SiO2) in 86% yield. 1H NMR (CDCl3, 500 MHz) δ
5.171 (t, J = 7 Hz, 1 H), 2.190-2.245 (m, 4 H), 1.980 (t, J = 8 Hz, 2 H), 1.941 (t, J = 1 Hz, 1 H),
1.612 (s, 3 H), 1.267-1.397 (m, 18 H), 0.888 (t, J = 6.5 Hz, 3 H); 13C NMR (CDCl3, 125 MHz) δ
132.419, 117.372, 79.837, 63.283, 34.879, 27.171, 24.894, 24.806, 24.600, 24.508, 23.143,
22.407, 17.933, 14.191; HRMS (ESI) calcd for C18H32 [M+H]+: 249.2504, found: 249.2503.

To a solution of 2-16 (3 g, 12.3 mmol) in 20 mL of dry THF, n-BuLi (4.92 mL, 2.5 M)
was added dropwise at -78 °C. The solution was stirred at -40 °C for 30 mins then, cooled to 78 °C. Garner’s aldehyde (2.8 g, 12.3 mmol) was added. The solution was stirred overnight.
Saturated NH4Cl was added to quench the reaction. The mixture was extracted with DCM and
dried over Na2SO4. 2.2 g of the product was isolated through a column chromatography (SiO2)
in 37 % yield. 1H NMR (CDCl3, 500 MHz) δ 5.130 (br, 1 H), 4.663 (br, 1 H), 4.568 (br, 1 H),
3.920-4.141 (m, 3 H), 2.594 (s, 1 H), 2.210 (br, 4 H), 1.959 (t, J = 7.5 Hz, 2 H), 1.593 (s, 3 H),
1.357-1.400 (m, 18 H), 0.886 (t, J = 7.0 Hz, 3 H); HRMS (ESI) calcd for C10H17ISi [M+H]+:
448.3818, found: 448.3824.
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To a blue solution of Li (230 mg, 32 mmol) in 10 mL of EtNH2, 2-17 (2.6 g, 6 mmol) in 5
mL of dry THF was added at -78 °C. The solution was stirred for 2 hrs. 2 g of NH4Cl was
added to quench the reaction. After the solvent was removed, the residue was extracted with
Et2O. 1.2 g of the product was obtained through a column chromatography (SiO2) in 59% yield.
1

H NMR (CDCl3, 500 MHz) δ 5.755 (dt, J = 15.5, 6.5 Hz, 1 H), 5.486 (dd, J = 15.5, 7.0 Hz, 1 H),

5.090 (br, 1 H), 4.041 (t, J = 6 Hz, 1 H), 3.619-3.660 (m, 2 H), 2.845 (br, 1 H), 2.315 (br, 1 H),
2.300 (br, 1 H), 2.095 (br, 4 H), 1.952 (t, J = 7.5 Hz, 2 H), 1.580 (s, 3 H), 1.300-1.393 (m, 18 H),
0.882 (t, J = 7.0 Hz, 3 H); 13C NMR (CDCl3, 125 MHz) δ 136.204, 134.232, 129.601, 123.159,
73.807, 66.724, 62.578, 39.700, 32.560, 31.915, 29.688, 29.657, 29.642, 29.566, 29.352, 29.326,
27.994, 27.308, 22.685, 15.987, 14.111; HRMS (ESI) calcd for C21H41NO2 [M+H]+: 340.3137,
found: 340.3145.

To a solution of NaN3 (1.3 g, 20 mmol) in 10 mL of water, 10 mL of DCM was added.
Tf2O (1.13 g, 4 mmol) was added to the solution at 0 °C, and the mixture was stirred for 2 hrs.
The organic layer was used to dissolve 720 mg of compound 2-18. Then, K2CO3 (272 mg, 2
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mmol) and CuSO4.5H2O (5 mg, 0.02 mmol) were added to the solution. The mixture was stirred
overnight at room temperature.

620 mg of the product was isolated through a column

chromatography (SiO2) in 85% yield. 1H NMR (CDCl3, 500 MHz) δ 5.600 (dt, J = 15.5, 6.5 Hz,
1 H), 5.488 (dd, J = 15.5, 7.0 Hz, 1 H), 5.026 (t, J = 6.5 Hz, 1 H), 4.181 (t, J = 6 Hz, 1 H), 3.715
(br, 2 H), 3.439 (dd, J = 10.5, 5.5 Hz, 1 H), 1.996-2.056 (m, 4 H), 1.886 (t, J = 7.5 Hz, 2 H),
1.512 (s, 3 H), 1.190-1.326 (m, 18 H), 0.811 (t, J = 7.0 Hz, 3 H); 13C NMR (CDCl3, 125 MHz) δ
136.326, 135.567, 128.251, 122.987, 73.807, 66.724, 62.578, 39.681, 32.530, 31.915, 29.688,
29.657, 29.642, 29.566, 29.352, 29.326, 27.994, 27.308, 22.685, 15.987, 14.111; HRMS (ESI)
calcd for C21H39N3O2 [M+H]+: 366.3042, found: 366.3050.

To a solution of 2-19 (140 mg, 0.38 mmol) in 0.5 mL of dry pyridine, TDSCl (107 mg,
0.6 mmol) was added. The solution was heated to 70 °C for half an hour. BzCl (84.42 mg, 0.6
mmol) and DMAP (8.5 mg, 0.07 mmol) were added to the solution. After stirring for 1 hrs, the
solvent was removed. The residue was dissolved into 2 mL of THF. 5 mL of aqueous HF was
added and the solution was stirred for 1 hrs. The mixture was poured into 20 mL of saturated
NaHCO3. The mixture was extract with Et2O. 120 mg of the product was isolated through a
column chromatography (SiO2) in 76% yield for three steps.

1

H NMR (CDCl3, 500 MHz) δ

8.068 (d, J = 7 Hz, 2 H), 7.589 (t, J = 7.5 Hz, 1 H), 7.464 (d, J = 7.5 Hz, 2 H), 5.943-5.989 (m, 1
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H), 5.605-5.652 (m, 2 H), 5.082 (t, J = 5.5 Hz, 1 H), 3.819 (dd, J = 11.5, 4 Hz,1 H), 3.761 (dd, J
= 8.5, 4 Hz ,1 H), 3.638 (dd, J = 11.5, 8.5 Hz,1 H), 2.120 (m, 4 H), 1.930 (t, J = 7 Hz, 2 H),
1.567 (s, 3 H), 1.262-1.373 (m, 18 H), 0.888 (t, J = 6.5 Hz, 3 H); 13C NMR (CDCl3, 125 MHz) δ
166.027, 138.797, 136.921, 133.892, 130.360, 130.292, 129.044, 124.094, 123.407,
75.119,66.762, 62.517, 40.215, 33.151, 32.480, 30.211, 30.119, 29.902, 28.521, 27.686, 23.246,
16.544, 14.679; HRMS (ESI) calcd for C28H43N3O2 [M+H]+: 487.3304, found: 487.3308.

To a solution of 21 (120 mg, 0.2 mmol) in 1 mL of CCl3CN, 54.4 mg of K2CO3 was
added. The solution was stirred overnight. After filtration, the solvent was removed. The
residue and 2-20 (50 mg, 0.1 mmol) were dissolved into 2 mL of dry DCM. 20 mg of active 4A
molecular sieve was added. The mixture was stirred for half an hour. Two drops of TMSOTf
was added at 0 °C. The reaction was stopped by adding 50 μL of Et3N after 2 hrs. After
filtration, the solvent was removed. 130 mg of the product was isolated through a column
chromatography (SiO2) in 48% yield.
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To a solution of 2-22 (130 mg, 0.124 mmol) in 5 mL of acetic acid, Zinc (80 mg, 1.24
mmol) was added. The mixture was stirred overnight. After filtration, the solvent was removed,
and then, 112 mg of the product was obtained through a column chromatography (SiO2) in 78%
yield.

To a solution of palmitic acid (237 mg, 0.92 mmol) in 5 mL of THF, EDCI (191 mg, 0.93
mmol) and HOBT (125 mg, 0.93 mmol) were added. The solution was stirred for 30 mins, and
then, 250 mg of compound 2-23 was added.

The solution was stirred overnight at room

temperature. After removing the solvent, 310 mg of the product was isolated through a column
chromatography (SiO2) in 73% yield.

To a solution of 2-24 (310 mg, 0.225 mmol) in 1 mL of MeOH, fresh prepared 1 mol / L
NaOMe in MeOH was added. The solution was stirred 2 hrs. After the solvent was removed,
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the mixture was added 20 mL of DCM. After washed with 5 mL of brine and dried over
Na2SO4, the solvent was removed to yield 92 mg of the product. The yield was 83%.

To a solution of nonyl aldehyde (5.8 mL, 32 mmol) in 150 mL of DCM,
(carbethoxyethylidene)triphenylphosphorane (9.6 g, 32 mmol) was added. The mixture was
refluxed overnight. After removing the solvent, 6 g of the product was isolated through a
column chromatography (SiO2). The yield was 83%. 1H NMR (CDCl3, 500 MHz) δ 6.702 (t, J
= 7 Hz, 1 H), 4.096-4.142 (m, 2 H), 2.101 (q, J = 7.5 Hz, 2 H), 1.757 (s, 3 H), 1.374 (t, J = 6.5
Hz, 2 H), 1.192-1.266 (m, 12 H), 0.818 (t, J = 7.5 Hz, 3 H);

13

C NMR (CDCl3, 125 MHz) δ

168.311, 142.480, 127.798, 60.416, 32.036, 29.602, 29.572, 29.408, 28.831, 28.771, 22.823,
14.404, 14.198, 12.408; HRMS (ESI) calcd for C14H26O2 [M+H]+: 227.1933, found: 227.1939.

To a solution of 2-26 (3.76 mL, 25 mmol) in 50 mL of THF, n-BuLi (10 mL, 2.5 M) was
added dropwise at -78 °C. The solution was stirred at -40 °C for 30 mins then, cooled to -78 °C.
The starting material was added dropwise, and the temperature was allowed to rise up to room
temperature. The solution was stirred overnight. Saturated NH4Cl was added to quench the
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reaction. The mixture was extracted with hexanes and dried over Na2SO4. 2.8 g of the product
was isolated through a column chromatography (SiO2). The yield was 61 for two steps.

1

H

NMR (CDCl3, 500 MHz) δ 5.377 (t, J = 8.5 Hz, 1 H), 3.951 (s, 2 H), 2.227 (br, 1 H), 1.996 (q, J
= 6.5 Hz, 2 H), 1.628 (s, 3 H), 1.250-1.322 (m, 12 H), 0.861 (t, J = 7.5 Hz, 3 H);

13

C NMR

(CDCl3, 125 MHz) δ 136.58, 40.10, 27.77; HRMS (ESI) calcd for C12H24O [M+H]+: 184.1827,
found: 184.1836.

To a solution of triphenylphosine (2.8 g, 29.7 mmol) in 50 mL of dry THF, NCS (3.96 g,
29.7 mmol) was added at 0 °C. The resulting suspension was poured into 4.8 g of 2-27at 0 °C.
The temperature was allowed to rise up to room temperature. The suspension was stirred for 5
hrs. Then, the solvent was removed and the brown residue was cracked and washed with
hexanes. The filtrate was collected and the solvent was removed. Then hexanes was used to
extract it, and after removing the solvent, 2.1 g of the crude product was used in the next step
without any further purification).

1

H NMR (CDCl3, 500 MHz) δ 5.527 (t, J = 8.5 Hz, 1 H),

3.894 (s, 2 H), 1.996 (q, J = 6.5 Hz, 2 H), 1.621 (s, 3 H), 1.250-1.322 (m, 12 H), 0.881 (t, J = 7.5
Hz, 3 H); 13C NMR (CDCl3, 125 MHz) δ 136.58, 40.10, 27.77; HRMS (ESI) calcd for C12H23Cl
[M+H]+: 203.1488, found: 203.1494.
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To a solution of 1-TMS-1-propyne (3.76 mL, 25 mmol) in 50 mL of THF, n-BuLi (10
mL, 2.5 M) was added dropwise at -78 °C. The solution was stirred at -40 °C for 30 mins then,
cooled to -78 °C.

The starting material from the last step was added dropwise, and the

temperature was allowed to rise up to room temperature. The solution was stirred overnight.
Saturated NH4Cl was added to quench the reaction. The mixture was extracted with hexanes and
dried over Na2SO4. 2.8 g of the product was isolated through a column chromatography (SiO2).
1

H NMR (CDCl3, 500 MHz) δ 5.146 (br 1 H), 2.205-2.236 (m, 4 H), 1.969 (t, J = 7.5 Hz, 2 H),

1.607 (s, 3 H), 1.268-1.396 (m, 14 H), 0.883 (t, J = 7.5 Hz, 3 H), 0.143 (s, 9 H);

13

C NMR

(CDCl3, 125 MHz) δ 137.133, 122.524, 107.660, 84.378, 39.908, 32.169, 29.778, 29.572, 29.523,
28.152, 27.563, 22.932, 20.601, 16.243, 14.344, 0.348; HRMS (ESI) calcd for C18H34Si [M+H]+:
278.2430, found: 278.2438.

To a solution of 2-29 (2.8 g, 10 mmol) in 10 mL of MeOH, K2CO3 (1.38 g, 10 mmol)
was added. The mixture was stirred at room temperature overnight. The solvent was removed,
and the residue was extracted with hexanes. After removing the solvent, 2.1 g of the product was
isolated through a column chromatography (SiO2). 1H NMR (CDCl3, 500 MHz) δ 5.200 (t, J = 7
92

Hz, 1 H), 2.196-2.301 (m, 4 H), 1.947-1.995 (m, 2 H), 1.947 (t, J = 1 Hz, 1 H), 1.611 (s, 3 H),
1.269-1.328 (m, 18 H), 0.885 (t, J = 6.5 Hz, 3 H);

13

C NMR (CDCl3, 125 MHz) δ 133.139,

126.433, 84.688, 68.507, 38.694, 32.145, 29.978, 29.784, 29.572, 29.529, 29.359, 29.007, 28.740,
28.127, 22.926, 18.635, 17.840, 15.964, 14.350; HRMS (ESI) calcd for C15H26 [M+H]+:
207.2035, found: 207.2042.

To a solution of 2-30 (1.9 g, 9.2 mmol) in 20 mL of dry THF, n-BuLi (10 mL, 2.5 M)
was added dropwise at -78 °C. The solution was stirred at -40°C for 30 mins then, cooled to 78 °C. Garner’s aldehyde (2.5 g, 11.4 mmol) was added. The solution was stirred overnight.
Saturated NH4Cl was added to quench the reaction. The mixture was extracted with DCM and
dried over Na2SO4. 2.6 g of the product was isolated through a column chromatography (SiO2).
1

H NMR (CDCl3, 500 MHz) δ 5.160 (t, J = 6.5 Hz, 1 H), 4.568 (d, J = 8.0 Hz, 1 H), 4.512 (d, J =

8.0 Hz, 1 H), 3.907-4.131 (m, 3 H), 2.288 (t, J = 7.5 Hz, 2 H), 1.959 (t, J = 6.5 Hz, 2 H), 1.587 (s,
3 H), 1.506-1.514 (m, 15 H), 1.263-1.327 (m, 12 H), 0.881 (t, J = 7.0 Hz, 3 H); HRMS (ESI)
calcd for C26H45NO4 [M+H]+: 436.3421, found: 436.3409.
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To a blue solution of Li (230 mg, 32 mmol) in 10 mL of EtNH2, 2-31 (2.6 g, 6 mmol) in 5
mL of dry THF was added at -78 °C. The solution was stirred for 2 hrs. 2 g of NH4Cl was
added to quench the reaction. After the solvent was removed, the residue was extracted with
Et2O. The solution was dried over Na2SO4. The crude was obtained as a clear glass, and was
used in the next step directly.

To a solution of palmitic acid (237 mg, 0.92 mmol) in 5 mL of THF, EDCI (191 mg, 0.93
mmol) and HOBT (125 mg, 0.93 mmol) were added. The solution was stirred for 30 mins, and
then, 250 mg of compound 2-32 was added.

The solution was stirred overnight at room

temperature. Then, the product was peracetylate. After removing the solvent, 360 mg of the
product was isolated through a column chromatography (SiO2). 1H NMR (CDCl3, 500 MHz) δ
5.780 (dt, J = 15.5, 7.0 Hz, 1 H), 5.595 (d, J = 9.0 Hz, 1 H), 5.407 (dd, J = 15.5, 7.5 Hz), 5.285
(dd, J = 7.5, 7.0 Hz, 1 H), 5.118 (t, J = 5.5 Hz, 1 H), 4.437-4.467 (m, 1 H), 4.290 (dd, J = 11.5,
6.0 Hz, 1 H), 4.029 (dd, J = 11.5, 4.5 Hz,1 H), 2.123-2.175 (m, 4 H), 2.104-2.077 (m, 8 H),
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1.937-1.978 (m, 2 H), 1.587-1.602 (m, 2 H), 1.576 (s, 3 H), 1.254-1.315 (m, 40 H), 0.882 (t, J =
6.5 Hz, 3 H);
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C NMR (CDCl3, 125 MHz) δ 173.009, 166.027, 136.976, 134.103, 125.680,

124.478, 73.890, 62.844, 50.639, 39.137, 37.098, 32.139, 31.101, 30.069, 29.918, 29.881, 29.742,
29.614, 29.450, 28.152, 25.924, 22.908, 21.317, 21.026, 16.165, 14.325; HRMS (ESI) calcd for
C38H69NO5 [M+H]+: 620.5176, found: 620.5181.

To a solution of 2-33 (360 mg, 0.58 mmol) in 2 mL of MeOH, 2 mg of Na was added.
The solution was stirred for 5 hrs, and then the solvent was removed. The residue was dissolved
into 2 mL of dry pyridine, TDSCl (155 mg, 0.87 mmol) was added. The solution was heated to
70 °C for half an hour. AcCl (54.6 mg, 0.7 mmol) and DMAP (8.5 mg, 0.07 mmol) were added
to the solution. After stirring for 1 hrs, the solvent was removed. The residue was dissolved into
2 mL of THF. 5 mL of aqueous HF was added and the solution was stirred for 1 hrs. The
mixture was poured into 20 mL of saturated NaHCO3. The mixture was extract with Et2O. 260
mg of the product was isolated through a column chromatography (SiO2). 1H NMR (CDCl3, 500
MHz) δ 5.965 (d, J = 9.0 Hz, 1 H), 5.783 (dt, J = 15.5, 7.5 Hz, 1 H), 5.485 (dd, J = 15.5, 7.5 Hz,
1 H), 5.246 (t, J = 5.5 Hz, 1 H), 5.108 (t, J = 5.5 Hz, 1 H), 4.125 (br, 1 H), 4.106-4.139 (m, 2 H),
2.103-2.195 (m, 4 H), 2.057 (s, 3H), 2.014-2.044 (m, 2 H), 1.951-1.978 (m, 2 H), 1.587-1.062 (m,
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2 H), 1.576 (s, 3 H), 1.254-1.315 (m, 18 H), 0.882 (t, J = 6.5 Hz, 3 H); 13C NMR (CDCl3, 125
MHz) δ 173.628, 171.231, 136.957, 134,645, 133,995, 125.692, 125.522, 125.456, 125.031,
74.497, 66.158, 62.182, 53.540, 39.780, 39.143, 37.092, 34.682, 32.145, 31.047, 30.076, 29.918,
29.881, 29.772, 29.730, 29.590, 29.493, 28.152, 26.003, 25.936, 22.908, 21.396, 16.152, 14.325;
HRMS (ESI) calcd for C36H67NO4 [M+H]+: 578.5070, found: 578.5074.

To a solution of 2-10 (200 mg, 1 mmol) in 4 mL of CCl3CN, 160 mg of K2CO3 was
added. The solution was stirred overnight. After filtration, the solvent was removed. The
residue and 2-34 (160 mg, 0.27 mmol) were dissolved into 5 mL of dry DCM. 70 mg of active
4A molecular sieve was added. The mixture was stirred for half an hour. Two drops of
TMSOTf was added at 0 °C. The reaction was stopped by adding 100 μL of Et 3N after 2 hrs.
After filtration, the solvent was removed. 130 mg of the product was isolated through a column
chromatography (SiO2). 1H NMR (CDCl3, 500 MHz) δ 7.293-7.501 (m, 15 H), 6.110 (d, J = 9.0
Hz, 1 H), 5.792 (dt, J = 15.5, 7.5 Hz, 1 H), 5.543 (s, 1 H), 5.408 (dd, J = 15.5, 7.5 Hz, 1 H),
5.332 (t, J = 7.5 Hz, 1 H), 5.108 (t, J = 5.5 Hz, 1 H), 4.624-4.968 (m, 4 H), 4.185 (br, 1 H), 4.026
(t, J = 7.5 Hz, 1 H), 3.968 (dd, J = 7.5, 1.5 Hz, 1 H), 3.788-3.809 (m, 1 H), 3.654 (t, J = 7.5 Hz, 1
H), 3.587-3.605 (m, 2 H), 3.338 (dd, J = 7.5, 1 Hz, 1 H), 1.833-2.165 (m, 11 H), 1.587 (s, 3 H),
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1.254-1.315 (m, 18 H), 0.882 (t, J = 6.5 Hz, 6 H);
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C NMR (CDCl3, 125 MHz) δ 172.973,

170.059, 138.778, 138.371, 137.594, 136.763, 134.208, 129.200, 128.782, 128.569, 128.472,
128.260, 128.199, 127.883, 127.750, 126.348, 125.425, 125.316, 101.718, 99.491, 82.533,
79.553, 78.794, 75.414, 74.188, 74.115, 69,235, 67.687. 63.008, 50.517, 39.204, 36.812, 32.169,
31.320, 30.094, 29.954, 29.808, 29.693, 29.614, 29.493, 28.176, 25.918, 22.938, 14.374; HRMS
(ESI) calcd for C63H93NO9 [M+H]+: 1008.6850, found: 1008.6854.

To a blue solution of Na (23 mg, 1 mmol) in 5 mL of liquid NH3, 10 (50 mg, 0.05 mmol)
in 1 mL of dry THF was added at -78 °C. The solution was stirred for 2 hrs. 2 g of NH4Cl was
added to quench the reaction. After the solvent was removed, the residue was extracted with
Et2O. 12 mg of the product was obtained through a column chromatography (SiO2). 1H NMR
(CDCl3, 500 MHz) δ5.798 (dt, J = 15.5, 7.5 Hz, 1 H), 5.479 (t, J = 10.0 Hz, 1 H), 5.341-5.434 (m,
2 H), 5.280 (t, J = 7.5 Hz, 1 H), 4.971-5.010 (m, 2 H), 4.886 (dd, J = 10.0, 4.0 Hz, 1 H), 4.3474.381 (m, 1 H), 4.222 (dd, J = 7.5, 3.5 Hz, 1 H), 4.095 (dd, J = 7.5, 2.0 Hz, 1 H), 3.952-3.977 (m,
1 H), 3.720 (dd, J = 11.0, 7.5 Hz, 1 H), 3.540 (dd, J = 11.0, 3 Hz, 1 H), 1.833-2.165 (m, 6 H),,
1.587 (s, 3 H), 1.254-1.315 (m, 18 H), 0.882 (t, J = 6.5 Hz, 3 H); 13C NMR (CDCl3, 125 MHz) δ
172.991, 170.490, 137.388, 131.531, 129.085, 1125.316, 96.748, 73.156, 70.722, 70.267, 69,035,
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67.700. 62.025, 50.736, 37.080, 32.837, 32.606, 32.151, 29.469, 26.015, 22.914, 21.305, 20.923,
20.862, 14.338; HRMS (ESI) calcd for C40H75NO8 [M+H]+: 698.5493, found: 698.5500.

To a suspension of CuCN (9.02 g, 100.8 mmol) in 200 mL THF, 84.8 mL of 2 M BuLi
was added dropwise under -78 °C. The temperature was stirred at -40 °C for 10 mins, and then
recooled down to -78 °C. Bu3SnH (60 mL, 212 mmol) was added over 1 hr, and then 1hydroxyl-2-butyne (7.1 g, 100.8 mmol) was added. The mixture was stirred overnight and the
temperature was allowed to rise up to room temperature. Saturated NH4Cl was added to quench
the reaction. After filtration, the solvent was removed. 25 g of the product was obtained through
a column chromatography (SiO2) in 93% yield. 1H NMR (CDCl3, 500 MHz) δ 6.409 (t, J = 2.0
Hz, 1 H), 4.260 (d, J = 2.0 Hz, 2 H), 1.89 (s, 3 H), 1.46-1.52 (m, 6 H), 1.27-1.35 (m, 6 H), 0.880.92 (m, 15 H);
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C NMR (CDCl3, 125 MHz) δ 136.58, 40.10, 27.77; HRMS (ESI) calcd for

C16H34OSn [M+H]+: 326.1632, found: 326.1638.

To a solution of the starting material (25 g, 60 mmol), I2 (15.4 g, 60 mmol) was added at
0 °C. The reaction mixture was stirred 0.5 hrs. After removing the solvent, 12 g of the product
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was isolated through a column chromatography (SiO2) in 99% yield.

1

H NMR (CDCl3, 500

MHz) δ 6.409 (t, J = 7.8 Hz, 1 H), 4.096 (d, J = 7.8 Hz, 2 H), 2.459 (s, 3 H); 13C NMR (CDCl3,
125 MHz) δ 136.58, 40.10, 27.77; HRMS (ESI) calcd for C4H7IO [M+H]+: 198.9542, found:
198.9545.

To a solution of triphenylphosine (19 g, 75 mmol) in 50 mL of dry THF, NCS (10 g, 75
mmol) was added at 0 °C. The resulting suspension was poured into 10 g of 1 at 0 °C. The
temperature was allowed to rise up to room temperature. The suspension was stirred for 5 hrs.
Then, the solvent was removed, and the brown residue was cracked and washed with hexanes.
The filtrate was collected and the solvent was removed. Then hexanes was used to extract it, and
after removing the solvent, the crude product was used in the next step without any further
purification. The crude yield was 81%. 1H NMR (CDCl3, 500 MHz) δ 6.422 (t, J = 7.8 Hz, 1 H),
3.962 (d, J = 7.8 Hz, 2 H), 2.495 (s, 3 H); 13C NMR (CDCl3, 125 MHz) δ 136.58, 40.10, 27.77;
HRMS (ESI) calcd for C4H6ClI [M+H]+: 216.9203, found: 216.9209.
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To a solution of 1-TMS-1-propyne (6.74 g, 60 mmol) in 100 mL of THF, n-BuLi (24
mL, 2.5 M) was added dropwise at -78 °C. The solution was stirred at -40 °C for 30 mins then,
cooled to -78 °C. 11 g of the starting material was added dropwise, and the temperature was
allowed to rise up to room temperature. The solution was stirred overnight. Saturated NH4Cl
was added to quench the reaction. The mixture was extracted with hexanes and dried over
Na2SO4. 11.5 g of the product was isolated through a column chromatography (SiO2) in 77%
yield. 1H NMR (CDCl3, 500 MHz) δ 6.192 (t, J = 1 Hz, 1 H), 2.403 (s, 3 H), 2.237-2.289 (m, 4
H), 0.159 (s, 9 H);
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C NMR (CDCl3, 125 MHz) δ 139.057, 105.843, 95.209, 85.444, 29.734,

27.697, 19.435, 0.082; HRMS (ESI) calcd for C10H17ISi [M+H]+: 293.01, found: 293.01.

A mixture of the trans-1-Nonenylboronic acid (6.7 g, 39.4 mmol), palladium(0)-trisk(triphenyl phosphine) (4.6 g, 4 mmol), cesium carbonate (12.8 g, 39.4 mmol) and the starting
material (11.5 g, 39.4 mmol) in 200 mL of THF was refluxed overnight. After cooling down and
filtration, the solvent was removed.

6.7 g of the product was isolated through a column

chromatography (SiO2) in 59% yield. 1H NMR (CDCl3, 500 MHz) δ 6.057 (d, J = 15.5, 1 H),
5.600 (dt, J = 15.5, 7.0 Hz, 1 H), 5.389 (t, J = 7.5 Hz, 1 H), 2.261-2.376 (m, 4 H), 2.053-2.111
(m, 2 H), 1.749 (s, 3 H), 1.253-1.404 (m, 10 H), 0.887 (t, J = 7 Hz, 3 H), 0.116-0.179 (m, 9 H);
δ 134.987, 134.266, 128.686, 127.675, 84.212, 68.337, 32.865, 31.828, 29.650, 29.223, 29.196,
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27.342, 22.662, 18.764, 14.092, 12.562, 0.082; HRMS (ESI) calcd for C19H34Si [M+H]+:
291.2403, found: 291.2452.

To a solution of 4 (6.7 g, 23 mmol) in 50 mL of MeOH, K2CO3 (3.1 g, 23 mmol) was
added. The mixture was stirred at room temperature overnight. The solvent was removed, and
the residue was extracted with hexanes. After removing the solvent, 4 g of the product was
isolated through a column chromatography (SiO2) in 80% yield. 1H NMR (CDCl3, 500 MHz) δ
6.066 (d, J = 15.5 Hz, 1 H), 5.609 (dt, J = 15.5, 7.0 Hz, 1 H), 5.394 (t, J = 7.5 Hz, 1 H), 2.3482.390 (m, 2 H), 2.235-2.268 (m, 2 H), 2.068-2.110 (m, 2 H), 1.960 (t, J = 2.5 Hz, 1 H), 1.752 (s,
3 H), 1.284-1.405 (m, 10 H), 0.888 (t, J = 7 Hz, 3 H); 13C NMR (CDCl3, 125 MHz) δ 134.987,
134.266, 128.686, 127.675, 84.212, 68.337, 32.865, 31.828, 29.650, 29.223, 29.196, 27.342,
22.662, 18.764, 14.092, 12.562; HRMS (ESI) calcd for C16H26 [M+H]+: 219.2035, found:
219.2048.

To a solution of the alkyne (4 g, 18 mmol) in mL of THF, catecholborane (18 mL, 18
mmol) was added. The solution was reflux overnight. The solvent was removed and the mL of
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water was poured into the residue. After filtration, 3.2 g of the product was obtained. The yield
was 68%.
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Chapter 3. Development of TLR-2 and TLR-6 heterodimer binders and studies of their
immunology activies

3.1 Introduction
3.1.1 Immune systems
Immune systems are found in all plants and animals.1 They protect organisms against
diseases by recognizing and killing pathogens and tumor cells. To function properly, they need
to identify the agents from those intruders or tumor cells and discriminate them from the healthy
cells owned by the organisms.
Physical barriers are the first layers to protect organisms from pathogens, such as bacteria
and viruses. Once the first barrier is broken through by a pathogen, the mammalian immune
system begins to eliminate the intruder through two broad categories of the immune system:
innate immunity and acquired immunity. T cells, B cells, dendritic cells and macrophages are
the major immune cells in mammalian immune system.
Pattern recognition receptors (PRRs) identify microbial components, which are difficult
for the microorganism to change because usually they are important for the survival of the
microorganisms. These microbial structures are termed pathogen associated molecular patterns
(PAMPs). Different PRRs interact with specific PAMPs, and activate unique signaling pathways,
thus, responding to pathogens distinctively.
Innate immune responses target a large range of conserved microbial and pathogenic
components or antigens, including proteins, nucleic acids and carbohydrates, and constantly
105

screen for these conserved components via unique PRRs.

In contrast, adaptive immune

responses are specific to a foreign antigen and remain at rest until they encounter a component
expressing that specific antigen. 2

3.1.2 Toll like receptors
Substantial research has focused on toll like receptors (TLRs) due to their ability to
discriminate between large assortments of microbial stimuli.3 TLRs are integral components of
the innate immune system. To date, eleven TLRs have been identified and characterized. They
are PRRs that are expressed on the surface of macrophages, dendritic cells, B cells, some T cells,
and some non-immunological cells.1, 4
Depending on the PAMP, including lipopeptides, lipopolysaccharide, bacterial
lipoprotein, and lipoteichoic acid, certain TLRs will bind and signal an immune response. 5
Multiple studies have shown a proinflammatory immune response to the binding of TLRs with
the targeted antigen.
TLRs are type 1 membrane glycoproteins consisting of extracellular, transmembrane, and
intracellular signaling domains.9

The extracellular domain consists of leucine-rich repeating

motifs (Lxx) and the intracellular domain comprises a homologous Toll/1L-1R domain (TIR).1
The extracellular domain’s conserved Lxx motifs number 20~30 amino acids in length. These
motifs form a  sheet and an  helix connected by a loop to help form a horseshoe-like 3-d
conformation (see figure 3-1).1, 6 The TIR domains have a five-stranded  sheet, encompassed
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about by five  helices. The second  sheet and second  helix play a key role in TIR
dimerization. So, TLRs are likely to function as dimers, and most TLRs appear as homodimers.

Figure 3-1: Crystal structure of TLR2-TLR1 hetero-dimer complexed with the synthesized
triacylated lipopeptide Pam3CSK4.

3.1.3 TLR2 / TLR6 induce TH2 response
Different stimulators educate dendritic cells to secret different cytokines. IL-10 blocks
host protective inflammatory responses and promote anti-inflammatory T regulatory TH2
immune responses. However, high level of IL-10 is not sufficient to induce T regulatory type
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cells. The ratio of IL-12 to IL-10 produced by dendritic cells plays the key roll.TLR1, TLR2 and
TLR6 recognize lipopeptides, and TLR2 plays the major roll in detecting and recognizing lipid
components of pathogens. Different from other TLRs, TLR2 forms heterodimers with TLR1 or
TLR6. Each dimer has different ligand specificity and provides different immune responses.

Figure 3-2: Structures of Pam2CSK4 and Pam3CSK4

108

Figure 3-3: Computional crystal structures of Pam2CSK4 bound TLR2 and TLR6 heterodimer

Studies show that TLR1 / TLR2 heterodimer binds a triacylated lipopeptide, Pam3CSK4
(Figure 3-2) and induce TH1 responses. For TLR2 / TLR6 heterodimer (Figure 3-3), there is no
hydrophobic pocket for the third acyl chain, and the lipopeptide’s amine interacts with TLR6 via
hydrogen bond stabilization,5 so it binds a diacylated lipopeptide, Pam2CSK4, to generate a
regulatory anti-inflammatory TH2 immune response by promoting dendritic cell to secret
relative high level of interleukin-10 to IL-12.7

3.2 Result and disscussion
3.2.1 Design of TLR-1 / TLR-6 heterodimer binders
Based on the studies described above, we designed and synthesized two modified
structures of lipopetides, lipopeptide mimic (LPM) -1 and LPM-2 (Figure 3-4).
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Figure 3-4: Structures of LPM-1 and LPM-2

The differences between Pam2CSK4 and LPM-1 are: (1) the amino acid, next to cysteine,
is glycine in LPM-1, rather than serine. We used glycine because it is simpler, and in the
literature it is reported that there is little difference between compounds with the two different
amino acids. (2) We replaced the lysines with a polyamine. There is evidence that the only role
of these lysines is to provide solubility to the lipid, and this can be achieved with a polyamine,
which is much simpler. In addition, there would be no proteolytic degradation of the peptide
portion if a polyamine is used to replace a sequence of lysines.
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Figure 3-5: Computional crystal structures of LPM-2 binded TLR2 and TLR6 heterodimer

For LMP-2, we put a 3, 5-bistrifluoro phenyl urea on the cysteine amine. Due to
modeling of the Pam2CSK4 and TLR2 / TLR6 heterodimer complex shown in Figure 3-3
indicated that there is an unoccupied pocket right above the Pam2CSK4 cysteine amine. To find
a proper functional group covalently attached to the stimulator may promote TLR2 / TLR6
heterodimer formation over TLR1 / TLR2 dimer formation. There are two phenylalanines,
F343’ and F365’, located at the terminal of the unoccupied pocket.

We hope the two

trifluoromethyl group can be fixed by those two phenyl group by π-stack interaction (Figure 3-5),
so that we can obtain stronger stimulation and more TH2 respond in the end.
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3.2.2 Synthesis of 3-10
The synthesis of polyamine part of LMP-1 starts from 3-amino-propanol. Protecting the
amino group with Boc, 3-1 was produced.

After mesylation of the hydroxyl group, and

substitution with 3-amino-propanol, Boc2O was used to selectively protect the secondary amine
to give 3-2 (Scheme 3-1).

Scheme 3-1: Synthesis of 3-1

Mesylation followed by propane-1,3-diamine substitution, one equivalent of Fmocsuccinimidyl carbonate was used to selectively protect the primary amino group at 0 °C afforded
3-7. Then Boc2O was used to protect the secondary amine. Piperidine de-Fmoc generated 3-9
(Scheme 3-2). This route to make 3-9 is not quite satisfied, due to relatively low yield. The
bottle neck is the step to make 3-7. The selectivity is only about 7:3. The other route was
preformed to do the comparison.
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Scheme 3-2: Synthesis of 3-9

Instead of using propane-1, 3-diamine, 3-amino-propanol was used to do the substitution.
Then, the free secondary amine was selectively protected by Boc to generate 3-3.

After

mesylation, azide was used to replace the mesylate. Hydrogenation catalyzed by palladium on
carbon afforded intermediate 3-9 in quantitive yield (Scheme 3-3).
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Scheme 3-3: Alternative synthesis of 3-9

Coupling with Fmoc protected glycine, followed by removing Fmoc, gave 3-10, the
solubility improvement chain (Scheme 3-4).

Scheme 3-4: Synthesis of 3-10

3.2.3 Synthesis of 3-12
The synthesis of the LMP binding part starts from (Fmoc-Cys-Ot-Bu)2. After zinc
reduction under acidic conditions, the disulfide bond was cleaved. The thiol was used as
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nucleophile to attack (S)-glycidol to afford 3-11. Acylation of the diol generated the diester.
Mono esterification was observed as major in 1 hour. Prolonging the reaction time to 6 hours
gave the desired intermediate. Using trifluoroacetic acid to remove tert-butyl ester generated 312 (Scheme 3-5).

Scheme 3-5: Synthesis of 3-12

3.2.4 Synthesis of LMP-1 and LMP-2
3-13 was obtained by coupling 3-10 with 3-12, using EDCI and HOBt. Removing Fmoc
protecting group afforded 3-13. HCl in dioxane was used to do Boc deprotection to accomplish
the synthesis of LMP-1 (Scheme 3-6).
Reacting 3-13 with bistrifluoromethyl phenyl isocynate, followed by HCl / dioxane
deprotection gave LMP-2 (Scheme 3-7).
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Scheme 3-6: Achievement of LPM-1
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Scheme 3-7: Achievement of LPM-2

3.2.5 Results and discussion
Mice dendritic cells are used to test TLR responses, which are isolated using the
following procedure. The collagenase was diluted to 1:10 in plain RPMI. The spleen was taken
out onto a Petri dish containing RPMI (Gibco) from the sacrificed mice. Then, it was hold over
the 50ml tube with forceps, and the 1:10 collagenase was injected with the syringe to puff up the
spleen. The puffed up spleen was put into the 50ml tube containing about 5ml 1:10 collagenase.
The mixture was incubated in an incubator at 37 C for 45 minutes. 1ml HBS was put into 1.5
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eppendorf tubes for overlay. After 45 minutes incubation, 50mM EDTA (stock is at 500mM, so
add 1:10 dilution) was added to quench the reaction. The tubes were cooled on ice for 5 minutes
to stop the collagenase reaction. The spleen was transferred into a cell strainer (BD Falcon,
70uM Nylon. REF 352350) in a 50ml, then, meshed with a 1cc syringe plunger. The solution
was filtered and the filtration was stored in a 50ml tube. The cells were centrifuged at 1500rpm
for 5 minutes, then, washed with 5ml HBS to get rid of teh collagenase.(re-spin at 1500rpm for 5
minutes). The cell pellet was broken up by gently tapping bottom of the tubes and resuspended
in 5ml optiprep solution. In a 15 ml tube, 5ml of the cell suspension was mixed well. 1ml of
HBS was added slowly using a Pasteur pipette, while tilting the 15ml tube as horizontal as
possible. The mixture was centrifuged at 200 rpm for 30 minutes. The cells were taken out from
the interface with a Pasteur pipette, then, washed with 4 ml of HBS, and spin at 300g for 5
minutes.
The cells were dispersed into 106 / ml in RPMI and stimulated by adding Pam2 (100
ng/mL), Pam3 (100 ng/mL) as controls.

LPM1 and LPM2 were added at different

concentrations. The plates were incubated at 37 C for 24 hours or 48 hours. ELISA was used to
test IL-10 and IL-12p40 levels.
From the result we can see, the ratio of IL-10/IL-12 stimulated by LPM1 is not as high as
that by Pam2. However, for TLR2 knocked out mice, both LPM1 and LPM2 didn’t stimulate the
dendritic cells to secret IL-10, and for TLR6 knocked out mice, not much IL-10 was detected
with LPM1 stimulation, but for wild type mice dendritic cells, a substantial jump of IL-10 was
observed. That argues that LPM1 is a better TLR6 depended stimulator than Pam2, which
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confirmed our previous hypothesis: polyamine will do the same job with peptide chain KKKK in
natural Pam2. The results also show that we are on the right direction to develop a TLR6
dependent stimulator.
For LPM2, the TLR6 depended IL-10 release is not as good as LPM1.

The only

structural difference between them is the bistrifluoromethyl phenyl urea on the cystein amino
group. It was designed to fill the third pocket of the TLR2/TLR6 heterodimer to get a more
stable binding, but the result is not satisfied. The size of the functional group may be too large.
We are preparing other smaller alternatives to fulfill the job.

3.3 Experimental section

To a solution of 3-amino-1-propanol (20.64 g, 0.275 mol) in 200 mL of DCM, Boc2O (60
g, 0.275 mol) was added in portion. The solution was stirred overnight. 45 g of the product was
isolated through a column chromatography (SiO2) in 94% yield. 1H NMR (CDCl3, 500 MHz) δ
4.822 (br, 1 H), 3.636-3.668 (m, 2 H), 3.275-3.299 (m, 2 H), 3.097 (br, 1 H), 1.633-1.677 (m, 2
H), 1.439 (s, 9 H);

13

C NMR (CDCl3, 125 MHz) δ 158.797, 59.391, 37.055, 33.122, 28.589;

HRMS (ESI) calcd for C8H17NO3 [M+H]+: 176.1208, found: 176.1256.
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To a solution of 3-boc protected amino-1-propanol (3.2 g, 18.3 mmol) in 20 mL of DCM,
MsCl (2.4 g, 21 mmol) and Et3N (2.12 g, 21 mmol) were added at 0 °C. The temperature was
allowed to rise up to room temperature. The solution was stirred for 30 mins. Then, 10 mL of
water was used to wash the solution. The aqueous layer was extracted with DCM three times.
The combined organic layer was dried over Na2SO4. After the solvent was removed, 3-amino-1propanol (10.32 g, 0.14 mol) was added to dissolve the residue. The solution was stirred at
80 °C for 2 hrs. 3-amino-1-propanol was removed under vaccum. 50 mL of water was used to
wash the solution. The aqueous layer was extracted with DCM three times. The combined
organic layer was dried over Na2SO4. After removing the solvent, the residue was dissolved into
50 mL of DCM. Then, Boc2O (4 g, 18.3 mmol) was added. The solution was stirred overnight.
4.8 g of the product 3-1 was isolated through a column chromatography (SiO2) in 79% yield. 1H
NMR (CDCl3, 500 MHz) δ 3.475-3.054 (m, 8 H), 1.807-1.591 (m, 4 H), 1.413 (s, 9 H), 1.367 (s,
9 H); 13C NMR (CDCl3, 125 MHz) δ 163.851, 158.797, 83.078, 80.677, 79.704, 66.490, 46.368,
44.971, 37.284, 28.445, 28.430, 28.414, 27.772, 27.753, 27.110, 22.257; HRMS (ESI) calcd for
C16H32N2O5 [M+H]+: 333.2311, found: 333.2316.

To a solution of 3-2 (4.8 g, 14.4 mmol) in 50 mL of DCM, MsCl (2.0 g, 17.5 mmol) and
Et3N (1.8 g, 17.5 mmol) were added at 0 °C. The temperature was allowed to rise up to room
temperature. The solution was stirred for 30 mins. Then, 10 mL of water was used to wash the
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solution. The aqueous layer was extracted with DCM three times. The combined organic layer
was dried over Na2SO4. After the solvent was removed, 3-amino-1-propanol (10.32 g, 0.14 mol)
was added to dissolve the residue. The solution was stirred at 80 °C for 2 hrs. 3-amino-1propanol was removed under vaccum. 50 mL of water was used to wash the solution. The
aqueous layer was extracted with DCM three times. The combined organic layer was dried over
Na2SO4. After removing the solvent, the residue was dissolved into 50 mL of DCM. Then,
Boc2O (3.2 g, 15 mmol) was added. The solution was stirred overnight. 7.2 g of the product was
isolated through a column chromatography (SiO2) in 99% yield. 1H NMR (CDCl3, 500 MHz) δ
4.822 (br, 1 H), 3.754-3.117 (m, 12 H), 3.097 (br, 1 H), 1.696-1.568 (m, 6 H), 1.477 (s, 9 H),
1.437 (s, 9 H);

13

C NMR (CDCl3, 125 MHz) δ 156.958, 156.436, 156.422, 80.541, 58.231,

44.158, 42.196, 37.658, 33.065, 31.310, 30.395, 28.827, 28.403, 28.383, 27.647; HRMS (ESI)
calcd for C24H47N3O7 [M+H]+: 490.3414, found: 490.3468.

To a solution of 3-3 (3 g, 6 mmol) in 20 mL of DCM, MsCl (0.755 g, 6.6 mmol) and
Et3N (667 mg, 6.6 mmol) were added at 0 °C. The temperature was allowed to rise up to room
temperature. The solution was stirred for 30 mins. Then, 20 mL of water was used to wash the
solution. The aqueous layer was extracted with DCM three times. The combined organic layer
was dried over Na2SO4. After the solvent was removed, ethylene diamine (3.6 g, 0.06 mol) was
added to dissolve the residue. The solution was stirred at 80 °C for 2 hrs. Then, ethylene
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diamine was removed under vaccum. 20 mL of water was used to wash the solution. The
aqueous layer was extracted with DCM three times. The combined organic layer was dried over
Na2SO4. After removing the solvent, the residue was dissolved into 5 mL of DCM. Then, 9fluroenylmethyl N-succinimidyl carbonate (2 g, 6 mmol) was added. The solution was stirred
overnight. 3 g of the product was isolated through a column chromatography (SiO2) in 53%
yield.

To a solution of 3-4 (3 g, 5.6 mmol) in 5 mL of DCM, Boc2O (3.2 g, 15 mmol) was
added. The solution was stirred overnight. 0.5 mL of Piperidine was then added into the
solution. After stirring for 1 hrs, the solvent and the piperidine were removed. 2.4 g of the
product was isolated through a column chromatography (SiO2) in 88% yield.

To a solution of 3-3 (4.8 g, 14.4 mmol) in 50 mL of DCM, MsCl (2.0 g, 17.5 mmol) and
Et3N (1.8 g, 17.5 mmol) were added at 0 °C. The temperature was allowed to rise up to room
temperature. The solution was stirred for 30 mins. Then, 10 mL of water was used to wash the
solution. The aqueous layer was extracted with DCM three times. The combined organic layer
was dried over Na2SO4. After the solvent was removed, 15 mL of DMSO was added to dissolve
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the residue. Then, NaN3 (1.87 g, 28.8 mmol) was added and the mixture was stirred at 80 °C
overnight. The temperature was cooled to room temperature then, 50 mL of water and 50 mL of
DCM were added. The aqueous layer was extract with DCM three times and the combined
organic phase was dried over Na2SO4. After removing the solvent, the product was used in the
next step directly. 1H NMR (CDCl3, 500 MHz) δ 3.321-3.101 (m, 12 H), 1.809-1.651 (m, 6 H),
1.461 (s, 9 H), 1.453 (s, 9 H), 1.433 (s, 9 H); HRMS (ESI) calcd for C24H46N6O6 [M+H]+:
515.3479, found: 515.3523.

Route 1: To a solution of 3-7 (3 g, 5.6 mmol) in 5 mL of DCM, Boc2O (3.2 g, 15 mmol)
was added. The solution was stirred overnight. 0.5 mL of Piperidine was then added into the
solution. After stirring for 1 hrs, the solvent and the piperidine were removed. 2.4 g of the
product was isolated through a column chromatography (SiO2).

Route 2: To a solution of 3-8, the residue was dissolved into 10 mL of MeOH. 0.5 g of
Pd/C was added and the mixture was hydrogenated overnight under 1 atm. 3.1 g of the product
was isolated through a column chromatography (SiO2) in 44% yield for three steps.

1

H NMR

(CDCl3, 500 MHz) δ 4.681 (br, 1 H), 3.754-3.117 (m, 12 H), 1.696-1.568 (m, 6 H), 1.477 (s, 9
H), 1.437 (s, 9 H);

13

C NMR (CDCl3, 125 MHz) δ 156.958, 156.436, 156.422, 80.541, 58.231,
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44.158, 42.196, 37.658, 33.065, 31.310, 30.395, 28.827, 28.403, 28.383, 27.647; HRMS (ESI)
calcd for C24H48N4O6 [M+H]+: 489.3574, found: 489.3613.

To a solution of Fmoc-glycine (300 mg, 1 mmol) in 5 mL of DCM, EDCI (230 mg, 1.2
mmol) and HOBT (162 mg, 1.2 mmol) were added. The solution was stirred for 30 mins, then,
600 mg of compound 3-9 was added. The solution was stirred overnight at room temperature.
Piperidine was then added into the solution.

After stirring for 1 hrs, the solvent and the

piperidine were removed. 540 mg of the product was isolated through a column chromatography
(SiO2) in 81% yield.

To a solution of (Fmoc-Cys-Ot-Bu)2 (1.92 g, 2.4 mmol) in 15 mL of DCM, active zinc
powder (1.1 g, 16.8 mmol) and a freshly prepared mixture of MeOH, concentrated sulfuric acid
and concentrated HCl (100:1:7, 8 mL) were added under vigorous stirring. After 15 min (S)glycidol (355 mg, 4.8 mmol) was added. The mixture was stirred for 5 hrs. About half of the
solvent was evaporated. After filtration, 2 mL of saturated KHSO4 was added, then, extracted
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with DCM three times. The combined organic phase was dried over Na2SO4. After removing
the solvent, the product was purified through a column chromatography (SiO2) in 83% yield.

To a solution of 3-11 (946 mg, 2 mmol) in 10 mL of DCM, palmitoyl chloride (1.21 g,
4.4 mmol) and Et3N (444 mg, 4.4 mmol) were added at room temperature. The solution was
stirred overnight. 10 mL of water was added to wash the solution. The aqueous layer was
extracted with DCM three times. The combined organic phase was dried over Na2SO4. The
solvent was removed and 10 ml of DCM was added to dissolve the residue. 1.5 mL of TFA was
added, and the solution was stirred overnight. After removing the solvent and TFA, 1.5 g of the
product was isolated through a column chormotography (SiO2) in 84% yield. 1H NMR (CDCl3,
500 MHz) δ 4.681 (br, 1 H), 3.754-3.117 (m, 12 H), 1.696-1.568 (m, 6 H), 1.477 (s, 9 H), 1.437
(s, 9 H); 13C NMR (CDCl3, 125 MHz) δ 173.648, 173.589, 173.542, 172.277, 143.722, 141.288,
129.521, 127.740, 127.095, 126.558, 125.150, 119.986, 110.000, 70.325, 67.357, 63.650, 47.088,
45.895, 35.009, 34.296, 34.109, 32.816, 31.923, 29.703, 29.673, 29.661, 29.646, 29.501, 29.360,
29.288, 29.127, 29.104, 24.894, 24.852, 22.689, 14.115, 8.592; HRMS (ESI) calcd for
C24H48N4O6 [M+H]+: 489.3574, found: 489.3613.
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To a solution of 3-12 (163 mg, 0.18 mmol) in 2 mL of DCM, EDCI (39 mg, 0.2 mmol)
and HOBT (28 mg, 0.2 mmol) were added. The solution was stirred for 30 mins, then, 100 mg
of compound 3-10 was added.

The solution was stirred overnight at room temperature.

Piperidine was then added into the solution.

After stirring for 1 hrs, the solvent and the

piperidine were removed. 140 mg of the product was isolated through a column chromatography
(SiO2) in 65% yield.

To a solution of 3-13 (50 mg, 0.042 mmol) in 0.1 mL of dioxane, 0.2 mL of 4 N HCl in
dioxane was added. The solution was stirred overnight at room temperature, then, the solvent
was removed. 31 mg of LPM-1 HCl salt was obtained in 95% yield.
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To a solution of 3-13 (23 mg, 0.016 mmol) in 1 mL of 3, 5-di(trifluoromethyl)phenyl
isocynate (6 mg, 0.024 mmol) were added.

The solution was stirred overnight at room

temperature, and the solvent was removed. 20 mg of the product was isolated through a column
chromatography (SiO2) in 86% yield.

To a solution of 3-14 (20 mg, 0.017 mmol) in 0.1 mL of dioxane, 0.2 mL of 4 N HCl in
dioxane was added. The solution was stirred overnight at room temperature, then, the solvent
was removed. 18 mg of LPM-2 HCl salt was obtained in 92% yield.
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